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7AbstrACt
More than 6000 people in Sweden are diagnosed with colorectal cancer annually. One out of 
five patients already has metastases at diagnosis. However, the occurrences of metastases at 
specific locations, e.g. peritoneal carcinomatosis and ovarian metastases, are not well known. 
The development of surgical and oncological treatment strategies for primary tumours and 
metastatic disease has led to a need to discuss colorectal cancer patients in a multidisciplinary 
team (MDT). Although oncologic cure and overall survival are the main goals of treatment, 
quality of life and functional results are becoming increasingly important with the prolonged 
survival. While male sexual dysfunction after rectal cancer treatment has been well described, 
considerably less data have been published about the impact on women. In addition to surgical 
trauma, female androgen insufficiency could be a contributing factor to sexual dysfunction. 
Radiotherapy for rectal cancer may increase the risk of reduced ovarian androgen production, 
but there is scant information on this in the literature. 
Papers I-III are large population-based cohort studies reporting on the effects of the develop-
ment and implementation of MDT-conferences in patients with metastatic disease (Paper I) 
and the epidemiology of peritoneal carcinomatosis and ovarian metastases in colorectal cancer 
patients (Papers II–III). MDT assessment and metastasis surgery were more common in rectal 
cancer patients than in colon cancer patients, and the proportion increased over time. Peritoneal 
carcinomatosis was common, and risk factors were colon cancer, advanced tumour and nodal 
stage, fewer than 12 examined lymph nodes, emergency surgery, and a non-radical resection of 
the primary tumour. Ovarian metastases were uncommon, especially in rectal cancer patients. 
Paper IV assesses feasibility and internal and external validity in a prospective, observational 
cohort study on sexual function and androgen levels in women with rectal cancer. The methods 
were workable and the patients’ compliance was good. Comparison of clinical data from the 
study cohort with that of women who were eligible for inclusion but not included revealed a 
selection bias. Having a partner and sexual activity was more common among women who 
answered all questions in the questionnaires about sexual function compared with those who 
did not. A power calculation based on data from the first included patients showed that a larger 
sample size than initially planned for was needed.
In conclusion, an increasing proportion of patients with metastatic colorectal cancer were dis-
cussed by the MDT. Predictors for and the occurrence of peritoneal carcinomatosis and ovar-
ian metastases were defined, which may help to decide on individual treatment and follow-up 
regimens. The analysis of baseline data from the study on sexual function and androgen levels 
in women with rectal cancer indicates feasible methods but a selection bias. Inclusion of new 
patients in the study continues. 
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introduCtion
Epidemiology and Etiology
Colorectal cancer is one of the most common cancers worldwide. The highest incidence rates 
are found in Australia, North America and Western Europe, whilst the lowest are found in de-
veloping countries 75. In Sweden, colorectal cancer is the third most common form of cancer 
in both sexes, after prostate and skin cancer in men, and after breast and skin cancer in wom-
en.  In 2009, 3256 men and 2924 women were diagnosed with colorectal cancer 222. Incidence 
rates have increased slightly over the past decades (Fig. 1) 5 6. The incidence of cancer of the 
proximal colon is higher in women than in men, while men have a higher incidence of cancer 
in the distal colon and rectum 195. 
 Figure 1b. Age-standardized incidence of and mortality from colon cancer per 
 100.000 female inhabitants in Sweden, 1970–2009
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Figure 1a. Age-standardized incidence of and mortality from colon cancer per 
100.000 male inhabitants in Sweden, 1970–2009
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 Figure 1c. Age-standardized incidence of and mortality from rectal cancer per 
 100.000 male inhabitants in Sweden, 1970–2009
 Figure 1d. Age-standardized incidence of and mortality from rectal cancer per 
 100.000 female inhabitants in Sweden, 1970–2009
Predictors for developing colorectal cancer include hereditary factors, advanced age, male sex, 
previous polyps or colorectal cancer, inflammatory bowel disease, obesity, and diabetes mel-
litus 57 195. Associated lifestyle and dietary factors include low physical activity, a low intake 
of dietary fibers and high intake of fat and red meat, smoking, and high alcohol consumption. 
Studies on sex hormone-related factors report a decreased risk of colorectal cancer with en-
dogenous and exogenous estrogen exposure, as well as androgen deprivation therapy 31 65 85 
94. Some of the predictors may explain the geographical variations and the differences in inci-
dences between men and women.
Adenoma is the precursor to colorectal cancer. About 10% of adenomas progress to invasive 
cancers via several steps of genetic changes in a process lasting approximately 10 years 57 267 
. Kindred and twin studies estimated that approximately 30% of all colorectal cancers are an 
inherited form of the disease 57 115. The most common genetic syndromes are familial adenoma-
tous polyposis (FAP) syndrome and hereditary non polyposis colorectal cancer (HNPCC) syn-
drome, together accounting for about 5% of all colorectal cancers. 
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About 20% of patients with colorectal cancer already have metastatic disease at diagnosis of 
the primary tumour 5 6 53. The most frequently reported site for distant metastases is in the liver 
8 . The reason for this is the direct venous drainage from the bowel to the portal vein system. 
Other sites of metastatic disease that are specifically addressed in this thesis are the peritoneum 
and the ovaries. Knowledge about the epidemiology and risk factors of peritoneal carcinoma-
tosis (PC) is limited and population-based studies are lacking. Previously, synchronous and 
metachronous PC have been reported in 2-19% of colorectal cancer patients 117 131. Possible 
predictors of developing metachronous PC described in the literature are liver metastases, tu-
mour (T) stage, nodal (N) stage, venous and perineural invasion, synchronous limited PC diag-
nosed with the primary tumour, synchronous ovarian metastases, and perforated or obstructive 
primary tumour 71 117 264. The mechanisms causing PC are multifactorial and include hematog-
enous or lymphatic spread, peritoneal dissemination from serosal involvement of the primary 
tumour, and implantation of free cancer cells in lymph fluid or venous blood during surgery or 
in the case of perforation of the primary tumour 112 233. 
Similarily to PC, the occurrence of ovarian metastases in women with colorectal cancer is not 
well known. Previous studies from single centres report synchronous ovarian metastases in 
0–9% of women with colorectal cancer and metachronous ovarian metastases in 0.9%–7% 93 
101 127 209 274. Ovarian metastases are reported to be associated with PC and to be more common 
in relatively young women 49 74 127 147 198 240. The pathogenesis may be trancoelomic or lympho-
vascular 275.
Survival
The age-adjusted 5-year survival for colorectal cancer patients has increased substantially over 
time in Europe, in particular in rectal cancer patients, and it is high in Sweden 37 181. The rela-
tive 5-year survival for patients diagnosed with colon cancer in Sweden during 2005–2009 
was 65.4% for women and 60.9% for men 5. The corresponding figures for rectal cancer were 
64.1% and 60.9% 6. The strongest prognostic factor is tumour stage 109. In patients with local-
ized colorectal cancer, 5-year relative survival reaches 90%, compared to 5–15% in patients 
with metastatic disease 37. The only treatment achieving long-term survival in patients with 
metastatic disease is surgical resection of the primary tumour and the metastases. In patients 
with liver metastases, hepatic resection, when feasible, is associated with an improved progno-
sis 130. Five-year survival after potentially curative resection of liver metastases ranges between 
30% and 58% 219.
Peritoneal Carcinomatosis
Peritoneal carcinomatosis from colorectal cancer has been regarded as a terminal condition 
with a median survival historically reported to be around six months 48 117 208. More recent 
palliative chemotherapy protocols based on the use of oxaliplatin, irinotecan, and biological 
agents have resulted in an improved prognosis in stage IV colorectal cancer patients, with 
Introduction
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a median survival reaching 24 months 171 211 249. Unfortunately, none of these trials provide 
data on survival for patients with isolated peritoneal dissemination. In contrast, an increasing 
number of studies have reported long-term survival in PC patients treated with cytoreductive 
surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), in particular in those 
where complete cytoreduction can be achieved 70 154 258. The rationale is to use the combina-
tion of cytoreductive surgery to treat macroscopic disease with perioperative intraperitoneal 
chemotherapy to treat microscopic disease 238 239. This is the only strategy that has shown cura-
tive results for PC in a randomized controlled trial and international register studies 70 87 258. An 
update of the randomized controlled trial reported a 45% 5-year survival in patients receiving 
optimal cytoreduction and HIPEC followed by systemic chemotherapy 257. In a retrospective 
analysis of a multicentre cohort of more than 500 patients treated with CRS and HIPEC, me-
dian and 5-year overall survival were 30.1 months and 27 %, respectively 70. Two compara-
tive studies of patients with isolated PC have reported a median survival of 35-63 months in 
patients treated with CRS and HIPEC versus 17- 24 months in patients treated with aggressive 
systemic chemotherapy alone 72 79. 
Ovarian Metastases
Survival in women with ovarian metastases depends on whether surgery can make the patient 
free from tumour or not. Tumour confined to the ovaries or the pelvic cavity, unilateral ovarian 
involvement, a macroscopically radical resection, normal carcinoembryonic antigen (CEA) 
level, chemotherapy and a good performance status are independent favourable prognostic fac-
tors 49 80 127 144 . The reported median survival after resection of colorectal ovarian metastases 
is 31–61 months when complete resection can be achieved and 7–15 months when resection is 
incomplete 80 162 198.
Clinical Staging
Primary Tumour
Investigations for preoperative staging include radiology for colon and rectal cancer as well as 
digital examination and rectoscopy for rectal cancer. 
Computed tomography (CT) of the abdomen can be used for staging of the primary tumour 
in colon cancer patients. In patients with rectal cancer, ridgid rectoscopy is used to assess the 
distance of the tumour from the anal verge. Pelvic magnetic resonance imaging (MRI) gives 
detailed information on the primary rectal cancer and regional lymph nodes. This imaging 
modality distinguishes the mesorectal fascia (MRF), which forms the potential circumferential 
resection margin (CRM) 89. MRI is superior in evaluating the risk of a postoperative involve-
ment of this margin (CRM+), which helps to select patients for neoadjuvant treatment and also 
to evaluate treatment response prior to surgery 241. Diffusion-weighted MRI is a promising 
method for distinguishing between tumour and fibrosis after radiochemotherapy 107. Recent 
data report improved selection of complete responders to neoadjuvant radiochemotherapy us-
17
ing diffusion-weighted MRI compared to standard pelvic MRI 141. Endorectal ultrasound is 
sometimes indicated for assessing tumour growth within the bowel wall. It gives high resolu-
tion images within a limited field of view, and is therefore superior to MRI in assessing the 
mural invasion in superficial bowel layers 123. However, the technique is not accurate in the 
detection of mesorectal metastatic lymph nodes 139. 
Distant Metastases
Computed tomography (CT) of the abdomen and CT or x-ray of the lungs are used for the as-
sessment of distant metastases in both colon and rectal cancer. Contrast–enhanced ultrasound 
or liver-specific MRI can give additional information if CT is inconclusive. Peritoneal metas-
tases are sometimes diagnosed in preoperative radiological examinations even though early 
detection of PC is still a radiological challenge. According to an international consensus, con-
trast-enhanced multidetector CT is the procedure of choice in the evaluation of PC in patients 
eligible for CRS and HIPEC 270. However, the procedure is limited by the difficulty in early 
nodule detection in thin patients without ascites, which may be the case in many patients with 
early tumour dissemination. The sensitivity of preoperative CT in detecting peritoneal implants 
is influenced by lesion size. Secondary CT features may be helpful in identifying the disease. 
These include distortion, obstruction and wall thickening of the small bowel and obstruction 
of extrahepatic bile ducts. Unfortunately, when patients present with these CT features as well 
as the presence of para-aortic lymph node metastases, the disease is usually too advanced to be 
salvaged by CRS and HIPEC. Positron-emission tomography (PET) with the tracer fluorode-
oxyglucose plays an increasingly important role in the diagnosis, staging, and surveillance of 
malignant disease 26. The combination of functional PET data and detailed anatomical infor-
mation provided by CT in dual modality PET/CT further improves staging accuracy 15. Early 
results with regard to aiding the selection of patients for CRS and HIPEC are promising 186 
190. It is important, however, to know that a PET scan may not detect mucinous or low-grade 
malignant tumours and it can produce false positive results in cases of acute inflammation or 
active tissue repair, i. e., after surgery.
Ovarian metastases may be detected with CT, MRI, ultrasound or PET/CT 128. Typically CT 
and MRI show unilocular or multilocular cystic masses, associated with variable degrees of 
solid components (Fig. 2) 132. In the case of bilateral ovarian tumours, metastatic disease is 
likely since bilateral primary ovarian mucinous adenocarcinomas are rare.
Introduction
18
J. Segelman
 Figure 2. MRI presentation of bilateral ovarian metastases from rectal cancer (arrows). 
 UB: urinary bladder
Multidisciplinary Team Conference
Treatment of colorectal cancer involves specialists from multiple disciplines. With the devel-
opment of radiological staging and new treatment strategies, multidisciplinary team (MDT) 
conferences have become the model of care 140 173. The team includes surgeons, radiologists, 
oncologists, pathologists and specialized nurses. Each colorectal cancer patient should be dis-
cussed individually both pre- and postoperatively according to the guidelines of the National 
Board of Health and Welfare 224. Tumour stage, co-morbidity, social circumstances, and the 
wishes of the patient are taken into account. The aims are to facilitate communication and 
coordination between health care professionals and, above all, improve decision–making re-
garding optimal treatment for the individual patient. Through regular meetings, team members 
19
will become more aware of efficient ways of treatment planning, simplification of referral pro-
cesses, and avoidance of the duplication of examinations and investigations 206. MDT working 
should also provide team members with educational opportunities to learn about new treat-
ment developments and clinical trial recruitment. An association between the introduction of 
colorectal cancer MDT working with a change in treatment decisions has been reported 150. In 
an international study, MDT assessment influenced decisions about staging methods and neo-
adjuvant treatment of rectal cancer patients 17. Furthermore, in a study on treatment decisions 
at a colorectal cancer MDT, the vast majority of the decisions were implemented 269.  MDT 
discussion of MRI and implementation of a preoperative treatment strategy has been shown 
to reduce positive circumferential resection margins (CRM+) in patients with rectal cancer 
43. In a review examining the relationship between multidisciplinary cancer care and patient 
survival, a significant positive association was reported in 12 of 21 studies, including 3 on 
colorectal cancer 111. The proportion of colon and rectal cancer patients assessed by an MDT 
in Sweden has gradually increased. Differences between regions vary, in particular for colon 
cancer (Fig. 3) 5 6.
 Figure 3a. Proportion of patients assessed postoperatively by an MDT after elective 
 surgery for colon cancer, 2007–2010, by region. 
 Figure 3b. Proportion of rectal cancer patients assessed by an MDT before treatment 
 in Sweden, 2007-2010. 
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Figur 25a. Andel postoperativ bedömning i multidisciplinär terapigrupp för operera-
de patienter, 2007-2010, uppdelat på region, akut opererade.
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Figur 25b. Andel postoperativ bedömning i multidisciplinär terapigrupp för operera-
de patienter, 2007-2010, uppdelat på region, elektivt opererade.
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Tabell 14: Preterapeutisk bedömning i
multidisciplinär grupp 2010
Nej Ja Uppgift saknas Totalt
Stockholm/Gotland 48 301 0 349
(14) (86) (0)
Uppsala/Örebro 56 410 2 468
(12) (88) (0)
Sydöstra 45 166 0 211
(21) (79) (0)
Södra 60 286 4 350
(17) (82) (1)
Västra 77 282 1 360
(21) (78) (0)
Norra 33 141 2 176
(19) (80) (1)
Totalt 319 1586 9 1914
(17) (83) (0)
Figur 14: Preterapeutisk bedömning i multidisciplinär grupp 2007-2010
uppdelat på kön
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Histopathological Staging
Tumour, Node, Metastasis Staging
The most frequently used system for staging colorectal cancer is the TNM staging system, 
which is universal for all anatomic sites (Table 1) 221. The system has been developed by the 
International Union against Cancer (UICC) and the American Joint Commission of Cancer 
(AJCC) and has the primary advantage of being a detailed, independent classification within 
each subcategory (T, N, M). The relationship between the earlier Dukes’ classification and 
TNM systems is shown in Table 2 69.  
Table 1. TNM classification 7th edition221
TNM classification 7th edition
Primary tumour (T) TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria
T1 Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades through the muscularis propria into the subse-rosa or pericolorectal fat
T3a Minimal invasion: < 1 mm beyond the borders of the muscularis propria
T3b Slight invasion: 1–5 mm beyond the borders of the muscularis propria
T3c Moderate invasion: >5–15 mm beyond the borders of the muscu-laris propria
T3d Extensive invasion: > 15 mm beyond the borders of the muscula-ris propria
T4a Tumour penetrates to the surface of visceral peritoneum
T4b Tumour directly invades or is adherent to other organs or struc-tures
Regional lymph nodes (N) NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1–3 regional lymph nodes
N1a Metastasis in one regional lymph node
N1b Metastasis in 2–3 regional lymph nodes
N1c
Tumour deposit(s), i.e. satellites, in the subserosa, mesentery, or 
non-peritonealized pericolic or perirectal tissues without regional 
nodal mestastasis
N2 Metastasis in 4 or more regional lymph nodes
N2a Metastasis in 4–6 regional lymph nodes
N2b Metastasis in 7 or more regional lymph nodes
Distant metastasis (M) MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Metastasis confined to one organ or site (for example liver, lung, ovary, non-regional node)
M1b Metastases in more than one organ/site or the peritoneum
21
Table 2. Systems for classification of colorectal cancers 
AJCC/UICC staging system TNM classification 7th edition Dukes’ classification
Stage 0 Tis, N0, M0 -
Stage I t1–T2, N0, M0 a
Tumour limited to bowel wall
Stage II t3–4, N0, M0
Stage IIA: T3, N0, M0
Stage IIB: T4A, N0, M0
Stage IIC: T4B, N0, M0
B
Tumour growth outside the  
bowel wall
Stage III Any T, N1–N2, M0
Stage IIIA: 
T1–T2, N1, M0
T1, N2a, M0
Stage IIIB: 
T3–T4a,N1, M0
T2–T3, N2a, M0
T1–T2, N2b, M0
Stage IIIC: 
T4a, N2a, M0
T3–T4a, N2b, M0
T4b, N1–N2, M0 
c
Lymph node involvement
Stage IV Any T, Any, N M1
Stage IVA: Ant T, Any N, M1a
Stage IVB: Any T, Any N, M1b
d
Distant metastases
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Residual Tumour Classification
The tumour status regarding presence or absence of residual tumour after treatment is de-
scribed by the Residual (R) Tumour Classification (Table 3) 221. The R classification reflects 
the effects of treatment, influences further treatment planning and is a strong predictor of the 
prognosis 109.
Table 3. Residual Tumour Classification 
R0 No residual tumour
R1 Microscopic residual tumour
R2 Macroscopic residual tumour
Resection Margins
The CRM is the minimal distance from the outermost part of the tumour or malignant tissue 
to the lateral margin of the resected specimen. The malignant tissue could be a discontinuous 
spread of the primary tumour or, tumour in veins or lymphatic tissue. For parts of the bowel 
that are nearly totally enclosed by the peritoneum (ceacum, transverse and sigmoid colon), the 
CRM constitutes the mesenteric resection margin. Involvement of the CRM has a negative im-
pact on local and distant recurrence rates and survival 102 176 196 214. Microscopic tumour growth 
in the resection margin or a minimal distance of <1 mm from the tumour to the resection mar-
gin has been considered to be CRM-positive (CRM+) in most studies. However, some studies 
indicate that a margin of 2 mm is a more relevant cut-off value 175.
Surgical Treatment
Colon Cancer
Surgery with resection of the colon segment containing the tumour and its regional lymph 
nodes is the primary treatment for colon cancer. Continuity is restored with a hand-sewn or 
stapled anastomosis, or a stoma is performed. Compared to traditional surgery, the more radi-
cal complete mesocolic excision (CME) is reported to be beneficial in terms of a greater lymph 
node yield 260. This finding may explain the low local recurrence rates and high survival after 
such surgery in reported consecutive series 110. The concept of CME is sharp dissection of the 
visceral fascia from the parietal one so as to result in complete mobilization of the entire me-
socolon covered by an intact visceral fascia layer on both sides thereby ensuring safe exposure 
and tying of the supplying arteries at their origin. This concept is gaining ground in Sweden. A 
possible increased risk of complications has to be taken into account, however, when adopting 
the technique of central dissection at the roots of the vessels. 
23
The standard surgical approach in Sweden is open surgery. In 2009, only 3% of resections for 
colon cancer were performed laparoscopically 5.  The laparoscopic technique has been evalu-
ated in randomized controlled trials, which have shown that it is not inferior to open surgery 
regarding cancer-free survival 44 118. 
Rectal Cancer 
The golden standard for rectal resection is total mesorectal excision (TME), which minimizes 
the risk of local recurrence and avoids injury to the autonomic nerves innervating the pelvic 
organs 105 106 151. The introduction of the TME technique has led to improved cancer-specific 
survival 160. TME surgery includes sharp dissection under direct vision in the avascular plane 
surrounding the mesorectum down to the pelvic floor. The superiority of the method compared 
to the traditional blunt dissection has been confirmed in histopathological studies 196. Theoreti-
cally, the hypogastric and pelvic nerves are identified and preserved. Even if nerves are pre-
served, however, injury may still occur as a result of retraction, devascularisation, and cautery. 
The inferior mesenteric artery may be divided close to the aorta and proximal to the origin 
of the left colic artery (high tie), with a theorectially more oncologically sound operation, as 
well as more accurate tumour staging 121. Alternatively, because of concerns regarding the risk 
of autonomous nerve damage and possible ischemia in the proximal bowel end with a risk of 
anastomotic leakage, the inferior mesenteric artery may be divided distal to the origin of the 
left colic artery (low tie).  
Anterior resection of the rectum with anastomosis is performed when an adequate distal tu-
mour margin can be achieved with an acceptable functional result. If the tumour is located in 
the upper third of the rectum, a partial mesorectal excision with perpendicular transsection of 
the mesorectum at least 5 cm below the tumour is considered to be sufficient. The anastomosis 
is most frequently performed with a circular stapling device. In tumours of the middle and dis-
tal part of the rectum the resected rectum can be replaced using a side- to-end-anastomosis  or 
J-pouch in order to mitigate the functional disorder 98 99 152.
Anastomotic leakage is a common complication with high morbidity and occurs in about 9% 
of Swedish patients after anterior resection for rectal cancer 6. The occurrence of clinically 
significant anastomotic leakages is reduced by the use of a temporary loop-ileostomy, which is 
therefore recommended after anterior TME-resections 161.
Abdominoperineal resection is performed when the tumour is situated in the distal part of the 
rectum or when unacceptable functional results are expected with an anastomosis. For the low-
lying rectal cancer, there is almost no mesorectal fat, and the risk of CRM+ or an R1/2 resection 
is imminent. Because of the anatomy of the pelvic floor, abdominal dissection will end up with 
a coned specimen with a waist at the entrance of the anal canal where the tumour is located. If 
the procedure is stopped from above and started earlier from below, the surgeon can follow the 
pelvic floor laterally, thereby creating a more cylindrical specimen and thus avoiding a positive 
CRM 259. 
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If the tumour invades adjacent organs, an extended surgical procedure is necessary 182. Depend-
ing on tumour growth and the expected reconstruction of organs, the operating team is often 
multidisciplinary, comprising vascular surgeons, urological surgeons and plastic surgeons be-
sides the colorectal surgeon. A carefully planned extended TME is mandatory to achieve an R0 
resection in patients with locally advanced rectal cancer. Involved adjacent organs are resected 
en bloc with the rectum – if necessary including the ureters, bladder, small bowel, pelvic floor, 
nerves, blood vessels and sacrum. In men, the prostate and the seminal vesicles and, in women, 
the uterus, ovaries and vagina are removed if necessary.
In the earliest and most favourable cases of rectal cancer, e.g. malignant polyps, a local proce-
dure using the transanal endoscopic microsurgery (TEM) technique can be appropriate. This 
technique can be used provided that the resection is radical (R0) and no signs of poor differen-
tiation or vessel invasion are present. 
Radiotherapy and Radiochemotherapy
Preoperative radiotherapy for rectal cancer reduces local recurrences and increases the cancer-
specific survival 1 3 45 47 122 159 250 . These benefits have to be weighed against the adverse side 
effects. Well-known acute and long-term complications include erythema of the skin, nausea 
and diarrhea, cystitis, lumbosacral plexopathy, osteoradionecrosis, impaired sphincter func-
tion, urinary and sexual dysfunction, increased risk of postoperative ileus, and a doubled risk 
of secondary malignancies 24 142 157 193. Optimal clinical staging is crucial to select patients who 
will benefit most from preoperative radiotherapy. Tumours can be classified as “good”, “bad” 
or “ugly” based on the MRI findings 27.  The Swedish national guidelines are based on this 
classification 2. Somewhat simplified, early rectal cancer (“good”) has a low risk of recurrence 
and should be treated with surgery alone, for intermediately advanced tumours (“bad”) with 
an otherwise unacceptable risk of local recurrence, short-course radiotherapy immediately fol-
lowed by surgery is recommended, and for the locally advanced cancers (“ugly”) with a high 
risk of non-radical resection, preoperative long-course radiochemotherapy and delayed surgery 
are recommended (Fig. 4) 90. In patients considered to be too frail for the combined modality 
therapy, a possible alternative is short-course radiotherapy with renewed clinical and radiologi-
cal evaluation after 6 weeks 189. 
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Figure 4. Neoadjuvant treatment of rectal cancer according to clinical stage. Modified from 
Blomqvist/Glimelius 27
Target Volume and Fractionation
Today radiotherapy is administered using a four-field technique. Information from CT is used 
for increased precision in target volume and optimal dose planning. 
The aim of short course radiotherapy (5 x 5 Gray during one week) in patients with ”bad” 
rectal cancers is to eradicate tumour cells in the surrounding tissues, i.e. primary mesorectal 
lymph nodes and secondary lymph nodes laterally, presacrally, and along the superior rectal 
artery. The anal canal is included in the target volume in low rectal cancers where an abdomi-
noperineal resection is scheduled. Surgery is performed within a week after termination of the 
radiotherapy. The optimal fractionation and timing to surgery remains controversial. An ongo-
ing randomized study, the Stockholm III trial, addresses these issues 188. 
In patients with locally advanced ”ugly” cancers, the target volume is modified according to the 
extent of the tumour. A daily dose of 1.8 Gray up to a total dose of 50.4 Gray is combined with 
chemotherapy. The purpose of this strategy is to attain resectability by tumour regression be-
fore surgery. The chemotherapeutic agent can serve as a radiosensitizer on the primary tumour 
and micrometastatic disease, thereby preventing distant metastases. Surgery is performed 6–8 
weeks after the radiochemotherapy. The addition of chemotherapy to radiotherapy improves 
local tumour control but also increases the risk of toxicity 32 34.
Chemotherapy
The chemotherapeutic drugs used for colorectal cancer include one old and well documented 
agent combined with a vitamin, two newer more efficient, but more toxic agents plus three new 
Favourable ”good” group Intermediate ”bad” group Advanced ”ugly” group
Mid/upper rectum T1-T3b
Low rectum T1-2
N0
Mid/upper rectum T3c/d
Low rectum T3
T4 with peritoneal or vaginal 
involvement only
N1/N2
T4 with overgrowth to pros-
tate, seminal vesicles, base 
of urinary bladder, pelvic side 
walls or floor, sacrum
Positive lateral lymph nodes
MRF clear MRF clear MRF involvement (MRF+)
Primary surgery Preop 5 x 5 Gy with immedi-
ate surgery
Preop RTCT or 5 x 5 Gy with 
delayed surgery
RTCT: Radiochemotherapy up to 50.4 Gy in 1.8-Gy fractions with 5-fluorouracil (5-FU). 
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targeted drugs. The old and most frequently used agent is 5-FU/folinic acid, with relatively 
limited acute side effects and no late adverse effects. The newer drugs are oxaliplatin and 
irinotecan which are used in combination with 5-FU. Oxaliplatin is used in the neoadjuvant, 
adjuvant, and palliative setting, and irinotecan is indicated for pallitive purposes. The targeted 
drugs are antibodies that inhibit the epithelial growth-factor receptor (cetuximab, panitumum-
ab) or binds to vascular endothelial growth factor (bevacizumab). They are indicated for pallia-
tive purposes, where a limited effect on survival is reported 210 248 249. However, the results from 
randomized trials evaluating the effect of targeted drugs in the adjuvant setting are disappoint-
ing, and they are not recommended for adjuvant treatment of stage II–III colorectal cancer 13 252. 
Several randomized studies have reported a decreased risk of recurrence after colon cancer 
resection using adjuvant chemotherapy. Treatment with 6 months of postoperative 5-fluorou-
racil (5-FU)/folinic acid reduces the relative risk of recurrence by 30% 155 168 268. Survival is 
increased nearly to the same extent. Adding oxaliplatin to 5-FU/folinic acid reduces the risk of 
recurrence by another 10-15% 14 100 273. However, chemotherapy is associated with negative and 
sometimes severe or fatal side effects. For example, persistent peripheral sensory neuropathy is 
a troublesome toxicity associated with oxaliplatin 14 273. 
Adjuvant chemotherapy is recommended for stage III and ”high-risk” stage II colon cancer 
patients, as the risk of recurrence is high (30–50%) 2 73 138. Risk factors include few examined 
lymph nodes, poor histopathologic differentiation grade and, vascular, lymphatic, or perineural 
invasion, bowel obstruction or perforation, pT4 stage, and CRM involvement. The results for 
colon cancer have not been reproduced in rectal cancer, and the Swedish national guidelines do 
not recommend routine adjuvant chemotherapy for patients with rectal cancer outside clinical 
trials 2 32 41. In patients with unresectable stage IV colon and rectal cancer, palliative chemo-
therapy prolongs survival 81 211. 
Treatment of Liver Metastases
The definition of resectable liver metastases has changed over the years and now focuses on 
the resection of all visible liver metastases while preserving enough functional liver remnant 
with an adequate vascular supply and biliary drainage 8. An increased use of improved neoadju-
vant chemotherapy protocols allows tumour downsizing and consequent resection 10. Advances 
in interventional radiology, in particular portal vein embolization and radiofrequency thermal 
ablation, have contributed to the management of patients with colorectal liver metastases 9 179. 
The rapid development of treatment strategies and the importance of careful patient selection 
require evaluation by the MDT.
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Treatment of Peritoneal Carcinomatosis
Cytoreductive Surgery and Peritonectomy Procedures
In 1980 Spratt et al. reported the use of combined surgical resections and heated intraperitoneal 
chemotherapy for the first time in a patient with pseudomyxoma peritonei 231. Since then, CRS 
plus intraperitoneal chemotherapy has reached the level of gold standard treatment for col-
orectal carcinomatosis, pseudomyxoma peritonei, and peritoneal mesothelioma. CRS consists 
of numerous surgical procedures depending on the extent of peritoneal tumour manifestation. 
Sugarbaker provides detailed technical descriptions of the surgery which may include parietal 
and visceral peritonectomy, greater omentectomy, splenectomy, cholecystecomy, resection of 
the liver capsule, small bowel resection, colonic and rectal resection, gastrectomy, lesser omen-
tectomy, pancreatic resection, hysterectomy, oophorectomy, and urinary bladder resection 235. 
Above all, systematic exploration of all compartments and subsequent clearance of the perito-
neal cavity is necessary to identify sites of disease. The aim is to obtain complete CRS. This 
goal needs to be weighed against the potential morbidity and functional results, with potential 
influence on the patient’s quality of life. Frequently, implants on the small bowel surfaces are 
the major limitation to complete cytoreduction, since extensive small bowel resection is as-
sociated with a poor functional outcome (Fig. 5) 233. The tumour found at the time of surgical 
exploration of the abdomen is quantified using the peritoneal cancer index (PCI) by Sugarbaker 
194. PCI comprises both the peritoneal implant size and distribution of the nodules on the peri-
toneal surface, and is valuable in assessment of prognosis and treatment planning in patients 
with PC (Fig. 6) 70. 
Figure 5. Peritoneal carcinomatosis on the small bowel.  
With the kind permission of Dr Haile Mahteme
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Laparoscopy may be performed to assess the extent of tumour growth on the small bowel and 
portal hepatis, in order to avoid laparotomy in patients where complete CRS is not feasible 82. 
After CRS, the residual disease is classified intraoperatively using an established score. The 
completeness of cytoreduction (CC) score described by Sugarbaker is recommended in con-
formity with an experts’ consensus 91. Cytoreduction is considered to be adequate if either no 
macroscopic tumour remains (CC-0) or if only nodules less than approximately 2.5 mm (CC-1) 
remain to allow tumour penetration of intraperitoneal chemotherapy 64 119 234. Median survival 
after inadequate cytoreduction is similar to that of palliative treatment only 208 258.
The abdomen and the pelvis are divided into 13 regions. The lesion size of the largest peritoneal implants are 
scored (0 -3) in each abdominopelvic region. They can be summated as a numerical score, which ranges from 
0-39. The PCI is calculated at the time of surgical complete abdominal and pelvic exploration.
Figure 6. Peritoneal carcinomatosis index and Completeness of Cytoreduction score
With the permission of the publisher, BioMed Central
Intraperitoneal Chemotherapy
Cytoreductive surgery can be combined with hyperthermic intraperitoneal chemotherapy 
(HIPEC), early postoperative intraperitoneal chemotherapy (EPIC) or sequential postopera-
tive intraperitoneal chemotherapy (SPIC), the first being the most common and standard today 
46. The pharmacokinetic rationale of intraperitoneal drug administration is based on the dose 
intensification that occurs because drug movement from the peritoneal cavity to plasma (peri-
toneal clearance) is generally slow relative to drug clearance from the body 64 119. This results 
in a higher concentration in the peritoneal cavity compared with plasma after intraperitoneal 
administration 63.
There are many variations in exposure techniques (i.e. open or closed wall), duration (30 to 120 
minutes), intraperitoneal temperatures (40 to 44 oC), type of perfusate, and flow rates 70.
Most groups use a drug dose based on calculated body surface area which is an accurate predic-
tor of drug metabolism, and in this regard is a useful predictor of systemic toxicity 205. Drugs 
selected for HIPEC are generally cell cycle phase-non-specific agents, characterized by a direct 
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cytotoxic effect and synergistic antitumoural activity with hyperthermia. Specific pharmacoki-
netic features, such as high molecular weight and water solubility, favour a prolonged retention 
of the drug in the peritoneal space and a low systemic absorption and toxicity profile, which 
is expressed by the favourable ratio between peritoneal and plasma concentrations. The most 
widely used drugs for colorectal PC are oxaliplatin, irinotecan, mitomycin C, cisplatin, and 
mephalan 229. The main Swedish centre that performs CRS and HIPEC for colorectal carcino-
matosis uses a regimen of oxaliplatin and irinotecan. Patients also receive concomitant intrave-
nous 5-FU and folinic acid 251. The open abdomen ”Coliseum“ technique is used to administer 
HIPEC and the duration of perfusion is 30 minutes (Fig.7) 213. 
Adding hyperthermia to intraperitoneal chemotherapy may increase tumour response by sev-
eral mechanisms. First, heat alone has a direct antitumour effect 120. Mild hyperthermia of more 
than 41oC induces selective cytotoxicity of malignant cells. Second, mild hyperthermia aug-
ments the cytotoxic effects of some chemotherapeutic agents 21 135 170. Third, experimental data 
suggest that hyperthermia may increase the penetration depth of the chemotherapy solution 
into tissues and tumour nodules 114.
Figure 7. Hyperthermic intraperitoneal chemotherapy administered with the”Coliseum” technique.
With the kind permission of Dr Haile Mahteme
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Indications and Contraindications
Many selection criteria have to be assessed in each patient: performance status, comorbidity, 
response to previous chemotherapies, histology grading, presence of extraabdominal or liver 
metastases, small bowel involvement and tumour volume assessed by the PCI. Combined re-
section of liver metastases with CRS and HIPEC has not been shown to influence survival in 
several studies 216 253. However, in a large multicenter study, liver metastases did have a nega-
tive prognostic influence in patients who had undergone complete CRS, which is the most im-
portant prognostic factor 70. Other prognostic factors are the extent of PC, the experience of the 
center, the lymph node status, and adjuvant chemotherapy. 
Second Look
Some authors advocate second-look surgery and HIPEC in an attempt to diagnose and treat 
PC at an early stage in high-risk patients 71 153. Two ongoing randomized controlled studies are 
evaluating this concept 50 202. Twelve months after resection of the primary tumour or after six 
months of adjuvant chemotherapy, patients who remain without evidence of colorectal cancer 
by imaging, physical examination and tumour markers are randomized to second-look surgery 
or standard-of-care surveillance. At laparotomy, all previous dissection planes are opened. If 
PC is detected, CRS and HIPEC are performed. When selecting patients with a possible benefit 
from second-look surgery and HIPEC, a knowledge of the epidemiology and risk factors of PC 
is essential. 
Morbidity and Mortality 
The morbidity and mortality seen in connection with CRS and HIPEC is reported to decrease 
with increasing experience 172. In centers with an experience of more than 200 procedures, the 
reported major morbidity and mortality rates are about 20% and 2% respectively 88 134 237. Major 
morbidity involves complications of surgery: anastomotic leakages, intraperitoneal sepsis, and 
hemorrage. Independent factors influencing morbidity are duration of surgery, extent of carci-
nomatosis, the number of anastomoses performed, and incomplete CRS. The main morbidity 
from HIPEC is haematological toxicity, which is reported to occur in 8–31% of patients. 
 
The Role of Oophorectomy
Oophorectomy
In the case of macroscopic ovarian metastases, bilateral salpingo-oophorectomy (SOEB) is ad-
vised even if ovarian metastasis is diagnosed unilaterally, since ovarian involvement is likely to 
be bilateral 174 240. Ovarian metastases are common in patients with PC, and SOE could be con-
sidered in patients undergoing CRS and HIPEC even when there is no macroscopic evidence 
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of tumour 74. However, in the main Swedish center that performs CRS and HIPEC, SOEB is 
not performed if the ovaries are without signs of disease. 
Routine prophylactic SOE in order to prevent ovarian metastases has previously been recom-
mended, but this has been debated 20 25 93. The procedure lacks scientific support, and it is not 
recommended in national guidelines today 178 225 243. In the only randomized trial on prohylactic 
oophorectomy in women with colorectal cancer, no microscopic ovarian metastases were found 
in any of the 77 patients with macroscopically normal ovaries randomized to oophorectomy 274. 
Benefits of the procedure are a reduced risk of primary ovarian cancer, resection of possible 
microscopic synchronous ovarian metastases, and prevention of the development of metachro-
nous ovarian metastases. The side effects are premature menopause in premenopausal women 
and an increased risk of androgen insufficiency in women of all ages. SOEB will reduce the 
serum levels of testosterone (T) by half and may be associated with sexual problems and a de-
crease in psychological well-being 61 76 143. Furthermore, SOE is a risk factor for osteoporosis, 
cardiovascular disease, and death 52 56 164 185 232. 
Risk of Primary Ovarian Cancer
The impact of radiotherapy for rectal cancer as a risk factor for secondary cancers has been 
analysed in some studies 24 126. The results are divergent. An increased risk of second malignan-
cies mainly within or adjacent to the irradiated volume was reported in a large cohort study. 
Another population-based cohort study reported a decreased risk of cancer of the prostate and 
an increased risk of cancer of the uterine cervix and corpus. No increased risk of primary ovar-
ian cancer was seen in either of these studies. 
Primary ovarian cancer is diagnosed in about 2% of the Swedish female population, with the 
highest incidence in women aged 60–64 years 226. The risk is increased in women with breast-
ovarian cancer syndrome (BRCA 1/2 mutation), with a cumulative risk for ovarian cancer 
at the age of 70 of 35–60% and 10–27%, respectively 124.  In patients with hereditary non-
polyposis colorectal cancer syndrome (HNPCC), the life-time risk of ovarian cancer is 7–12%, 
with a median age at diagnosis of 40–47 years 7 129 254.  In these patients, prophylactic SOE 
is an important component of ovarian cancer risk reduction 124 129. Furthermore, SOE before 
menopause reduces the risk of breast cancer in women with BRCA1/2 mutation as well as in 
the general population 125 184 199. 
Sexual Function and Colorectal Cancer
As the prognosis of colorectal cancer has improved, interest has shifted to include quality of 
life and late effects of the cancer and its treatment. In general, descriptive cross-sectional and 
longitudinal studies among colorectal cancer survivors have concluded that the overall health-
related quality of life after treatment is good 16 180 197. However, previous studies have identified 
several sexual dysfunctions experienced by colorectal cancer survivors. Among men, these 
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include erectile dysfunction and ejaculatory disorders 104 158 244. Among women, specific sexual 
dysfunctions include dyspareunia, impaired sexual desire, arousal, lubrication, and orgasms 104 
108. 
Moreover, relatively non-specific problems such as descreased level of sexual activity, lack of 
sexual enjoyment, and changes in body image have been identified in both men and women 
following treatment for colorectal cancer 96 218.  Sexuality and intimacy are considered central 
to a person’s well-being and are important aspects of the quality of life 103.  Poor sexual func-
tioning and reduced sexual satisfaction are risk factors for a worse quality of life in cancer 
survivors 28. 
In rectal cancer patients, preoperative radiotherapy, advanced age and complications to surgery 
are risk factors for postoperative sexual dysfunction 108 142 158 242. The type of surgery, presence 
of a stoma and low rectal tumours may also be associated with sexual dysfunction 108 116 242. 
While male sexual dysfunction after rectal cancer treatment has been well described, consider-
ably less data have been published about the impact on women 244. Methodological limitations, 
such as retrospective study design, small sample size, or lack of validated assessment tools, are 
common. 
Complications from radiotherapy for rectal cancer were described earlier (page 24). In men 
with rectal cancer treated with radiotherapy, subnormal serum levels of testosterone indicate 
permanent testicular dysfunction 38 40 272. In women, vaginal fibrosis, dryness and bleeding  may 
result from pelvic irradiation as well as decreased sexual arousal due to altered blood flow and 
denervation, infertility, and premature menopause 23 203. 
In both pre- and postmenopausal women, radiotherapy for rectal cancer may reduce ovarian 
androgen production, but there is scant information on this in the literature. Female andro-
gen insufficiency is associated with sexual dysfunction, reduced psychological well-being, and 
negative metabolic effects 60 78. As such, androgen insufficiency could be a contributing factor 
to sexual dysfunction in women treated for rectal cancer.
Assessment of Sexual Function in Women
Questionnaires, structured interviews, daily rating scales or log books have all been used to 
evaluate female sexual function and dysfunction. There is, however, a lack of standardized, 
internationally acceptable questionnaires that are validated in general populations and can be 
used in women with or without disease and a sexual partner. 
In colorectal cancer patients, the most frequently used questionnaires for evaluation of dif-
ferent aspects of quality of life, including sexual function, are the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) 244. In the 
colorectal cancer-specific QLQ-CR38 as well as the recently updated version, QLQ-CR29, 
evaluation of sexual problems is limited to women who have had intercourse in the last four 
weeks 230 261. In the QLQ-CR29, only two items address sexual function. 
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The Female Sexual Function Index (FSFI) is a questionnaire composed of 19 multiple-choice 
items designed to assess the multidimensional nature of female sexual function (Appendix) 204. 
Scores are calculated for six domains: sexual desire, arousal, lubrication, orgasm, satisfaction 
and dyspareunia. The domain scores can be summarized to a total score ranging from 2 to 36. 
An FSFI total score below 26.5 is considered to be pathological 262. The FSFI has been validat-
ed to measure sexual function in sexually active women 165 204.  It was originally developed for 
pharmacological clinical trials, but it has been used for a large number of clinical conditions, 
including colorectal cancer 30 108 116. In a review of 27 questionnaires addressing female sexual 
dysfunction, the FSFI reached the highest level of utility in clinical and research settings 86. 
Data on objective measurements of the genital physiological response are limited. Photop-
lethysmography has been used to measure local blood flow in the vagina in order to assess 
genital arousal 136 137 191. This instrument has been used after pelvic surgery, including a small 
prospective study on laparoscopic restorative proctocolectomy for ulcerative colitis or familial 
adenomatous polyposis (FAP) syndrome 266. A significant postoperative reduction in vaginal 
vasocongestion measured during sexual stimulation was reported. However, subjective sexual 
arousal, estimated lubrication, and sexual functioning were not diminished. 
MRI measurement of clitorial volume has been used to evaluate genital arousal during ex-
posure to erotic film. An increased clitorial volume was reported in healthy subjects 66. The 
method has also been used to evaluate response to siladenfil administration in women with 
female sexual arousal disorder 271. 
The new technology of thermography measuring infrared radiation has suggested that labial 
temperature change is correlated to sexual arousal 133. 
Ovarian Function and Androgen Production
The main androgens in women, listed in the descending order of their serum concentrations, 
include dehydroepiandrosterone sulphate (DHEAS), dehydroepiandrosterone (DHEA), an-
drostenedione (A-4), testosterone (T), and dihydrotestosterone (DHT). DHEAS, DHEA, and 
A-4 are regarded as pro-androgens since they require conversion to testosterone or DHT to 
show androgenic effects in target tissues 220. Androgen biosynthesis takes place in the adrenals 
and ovaries. Testosterone is produced mainly by the interstitial cells of the ovary, DHEAS 
by the adrenal cortex, and DHEA and A-4 are produced by both the ovary and adrenal cor-
tex. In peripheric tissues, testosterone is converted to DHT, the principal ligand for androgen 
receptors. Androgens are also precursor hormones for estrogen production in the ovaries of 
premenopausal women and for conversion to estradiol in peripheric tissues in both pre- and 
postmenopausal women 54. Androgen levels decline with age in adult women 42 95. In a large, 
cross-sectional study, testosterone levels in women declined steeply from age 18 to 34 years, 
with a more gradual decline in levels until a nadir in the mid-60s 61. The pattern was similar for 
A-4 and DHEAS. The decline is probably mainly a consequence of reduced adrenal production 
and not of natural menopause as the post-menopausal ovary is an ongoing site of testosterone 
production 11 42. 
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Only 1–2% of total circulating testosterone is free, while around 25% is weakly bound to al-
bumin and the remainder is strongly bound to sex hormone-binding globulin (SHBG) 255. Only 
the free fraction of T is biologically active.
The reference limit for total T in women is <2.5–3 nmol/litre. However, there is no defined 
cut-off level defining T insufficiency. Etiologic factors associated with androgen insufficiency 
in women include:
1. Ovarian (chemotherapy, irradiation, oophorectomy) 61 113 143
2. Adrenal (adrenal insufficiency, adrenalectomy)
3. Hypothalamic-pituitary (hypopituitarism)
4. Drug-related  (GnRH agonists/antagonists, corticosteroids, oral contraceptives, oral 
estrogen treatment) 51
5. Idiopathic
According to a consensus statement, no commercially available assays are sufficiently sensi-
tive or reliable for the low androgen levels in women 18. It was concluded that total androgen 
production is best reflected by the total testosterone concentration, and that it is necessary to 
consider SHBG levels in the assessment of bioavailable testosterone in women. 
Role of Hormones in Female Sexual Function 
Androgens
Although hormones play an important role in female sexual function, it has been difficult to 
show correlations between endogenous levels and various aspects of sexuality. This probably 
reflects the complexity and many factors (physiological, psychosocial, cultural) involved in 
female sexuality. Animal and human data suggest, however, that testosterone directly influ-
ences sexual behaviour and libido via androgen receptors in the CNS 83 163. Androgens are 
also involved in the genital physiological response through regulation of the smooth muscle 
and local blood flow 246. Increased vaginal blood flow after visual erotic stimulation has been 
demonstrated after sublingual testosterone administration 247. A direct effect of this increased 
vasocongestion is lubrication, as pressure in the small vessels of the vaginal wall increases 
and plasma transudate passively flows through the epithelium 76. Damage to autonomic nerves 
disrupt this process 22  200. Inadequate sexual arousal may be partly due to decreased blood flow 
to the sexually responsive organs. Testosterone has been considered to be the key hormone 
in sexual desire in both men and women. In several studies, exogenous testosterone has been 
shown to increase levels of sexual desire in premenopausal women and women after surgical 
or natural menopause 36 59 77 217. A Cochrane review concludes that the addition of testosterone 
to postmenopausal hormone replacement therapy (HRT) improves desire, arousal and other 
aspects of female sexual dysfunction 228. A small number of studies report a direct relationship 
between serum levels of endogenous testosterone and sexual desire and coital frequency 12 19 
187 201. However, other studies exploring the relationship between endogenous androgens and 
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sexual function have shown conflicting results 68 92 212. In the largest study exploring this rela-
tionship, no correlation was found between low scores in any of the sexual domains evaluated 
and low serum levels of total testosterone, free testosterone, or A-4 60. 
There is still much controversy and insufficient knowledge about Female Androgen Insuf-
ficiency (FAI) 4 35 245. In 2002, a Consensus Conference on androgens agreed that androgen 
insufficiency in women with adequate estrogen levels could lead to a diminished sense of 
well-being and energy, fatigue, and decreased sexual desire 18. A more recent position statement 
recommended against making a diagnosis of ”androgen insufficiency”, because of the lack of 
a well-defined clinical syndrome and normative data across the lifespan 263. 
Estradiol
There is consistent evidence for the importance of estradiol for normal vaginal lubrication. 
Estradiol deficiency after surgical or radiotherapy-induced menopause results in an atrophic 
vaginal epithelium which causes coital pain. The physiological post-menopausal reduction in 
estradiol is frequently associated with vaginal dryness, which improves with estradiol replace-
ment 207. In addition, improved sexual function, feelings of well-being, and mood have been 
reported following estradiol therapy in women with menopausal symptoms 62 67 177. 
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Aims of the thesis
The aims were to assess
- the effects of development and implementation of MDT assessment and  
treatment in patients with stage IV colon and rectal cancer 
- the incidence, prevalence and risk factors for colorectal peritoneal  
carcinomatosis (PC)
- the incidence, prevalence, clinical characteristics and prognosis of ovarian  
metastases in women with colorectal cancer 
- feasibility and internal and external validity in an ongoing prospective study  
on sexual function and androgen levels in women with rectal cancer
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PAtients And methods
Papers I-III are large population-based cohort studies including patients from the Regional 
Quality Registry for Colorectal Cancer. Paper IV is an analysis of bias and baseline data in 
prospective observational cohort study with ongoing inclusion of patients from multiple insti-
tutions. The origins of the cohorts and the number of patients in each study are presented in 
Table 4.
Table 4. Patients included in the studies
Paper Inclusion 
period
Follow-
up until
Origin of the 
cohort
Study cohort Number of 
patients
i 1995/96– 
2004
2006 All inhabitants in 
the Stockholm 
region
All patients with stage IV 
colorectal cancer 
1449 pa-
tients
ii 1995/96–2007 2010 All inhabitants in 
the Stockholm 
region
All patients with colorectal 
cancer of all stages 
11.124 pa-
tients
Outcome analysis; pa-
tients who had abdominal 
resection of a primary 
colorectal cancer stage I–
III and who were alive 30 
days postoperatively
7799 pa-
tients
iii 1995/96–2006 2008 All inhabitants in 
the Stockholm 
region
All women with colorec-
tal cancer of all stages, 
without  previous or syn-
chronous gynaecological 
cancer
4566 female 
patients
Outcome analysis; pa-
tients who had an R0 
resection of a stage I–III 
colorectal cancer and 
who had not undergone 
bilateral oophorectomy
2852 female 
patients
IV June 2008 – 
June 2011
Only 
baseline 
data
All 237 women 
with rectal cancer 
treated at any of 
the participating 
institutions. 
Eligible women scheduled 
to undergo abdominal 
surgery for stage I–III rec-
tal cancer who consented 
to join the study
82 female 
patients
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The Regional Quality Registry
The Stockholm Colorectal Cancer Study Group was set up in 1980. The group consists of 
surgeons, radiologists, oncologists and pathologists representing all the hospitals in the Stock-
holm-Gotland region. The aim is to improve outcome in patients with colorectal cancer. As a 
part of this, treatment guidelines and a Regional Quality Registry have been established. Clini-
cal and pathological data have been logged prospectively in the Registry since 1995 (rectal 
cancer) and 1996 (colon cancer). The Registry covers 100 % of the colorectal cancer patients 
in the region, according to the National Cancer Registry. The Regional Quality Registry in-
cludes detailed clinical data on patient and tumour characteristics, treatment of the primary 
tumour and follow-up. Up to three different locations of metastases can be registered in the 
database. From 2007 onward, additional information on, for example, ASA classification, sub-
classification of T4 stage, information on MDT assessment before and after surgery and open 
or laparoscopic surgery is also recorded. In addition to follow-up data from planned check-ups, 
unexpected events such as local recurrences or metachronous metastases are recorded. The 
register is frequently used in research projects and is regularly validated by cross-checking 
medical records, histopathology reports, and other registries (the Swedish Cancer Registry, the 
Cause of Death Register and the Stockholm County Council Registry). 
The Stockholm County Council Registry
This registry covers the in- and outpatient healthcare consumption of all 2.1 million inhabitants 
in the region and includes healthcare provider, length of hospital stay, diagnoses according to 
the International Classification of Diseases, and type of surgery performed.
Paper I
The study population consists of patients with stage IV colorectal cancer at diagnosis. Patients 
with tumours diagnosed at autopsy were not included. Information was taken mainly from the 
Regional Quality Registry. At the time of the study period, data on MDT assessment were not 
included in the Registry. Therefore, this information was taken from the Stockholm County 
Council Registry and was checked individually for every patient. An MDT conference was 
defined as a structured discussion of treatment strategies between at least a surgeon and an on-
cologist before or after surgery. Medical records were reviewed for patients who had additional 
operations and for patients treated postoperatively with RT. Surgical treatment includes resec-
tion of the primary tumour, and, in patients where the primary tumour was not resected, divert-
ing stoma, enteroanastomosis, or laparotomy only. Surgical procedures performed in other 
regions were not registered. The colon and rectal cancer patients were categorized into four 
different treatment groups according to resection of the primary tumour and surgery for metas-
tases, and data were analysed separately for these groups. Data were also analysed separately 
for the periods 1995–1999 and 2000–2004.
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Paper II
This study included patients with all stages of colorectal cancer. Patients with tumours diag-
nosed at autopsy were included in the study cohort. Data were obtained from the Regional 
Quality Registry. In certain patients data were validated against the Stockholm County Council 
Registry, medical records and/or histopathology reports. This validation was performed in pa-
tients with perforated primary tumours, ovarian and small bowel metastases, primary ovarian 
cancers, local recurrences, metastases in three different locations excluding PC, if three year 
follow-up data were missing or if the patient had died without any reported metastases or re-
currences. 
In the risk factor analysis, all patients alive 30 days after resection of a stage I–III colorectal 
cancer were included.
Peritoneal carcinomatosis was defined as micro- or macroscopic tumour growth in the perito-
neum or ascites containing cancer cells. Intra-abdominal local recurrences with tumour growth 
in the peritoneum were also defined as PC. Anastomotic or retroperitoneal recurrences or stage 
T4 tumours with serosal involvement or overgrowth on adjacent organs without separate peri-
toneal metastases were not defined as PC.
All cytoreductive surgery (CRS) combined with intraperitoneal chemotherapy during the study 
period was performed at the same referral center. The first patient from the study cohort was 
treated in 1999. Surgery was combined with sequential postoperative intraabdominal chemo-
therapy until 2003. Thereafter, HIPEC became standard. 
Paper III
This study included women with colorectal cancer of all stages, without a previous or synchro-
nous history of gynaecological cancer. Patients with primary tumours diagnosed at autopsy 
were included in the study cohort. Medical records and histopathology reports were reviewed 
for patients who had ovarian metastases, ovarian cancer, and for patients with missing follow-
up data. The diagnosis of ovarian metastases was confirmed by histopathology in at least 75 of 
79 patients.
In the analysis of the incidence of metachronous ovarian metastases, patients who underwent 
bilateral oophorectomy at the primary operation were not included as they were no longer at 
risk. 
Data were analysed separately for patients with colon and rectal cancer who had undergone 
a ”curative” resection, i.e. an R0 resection of a stage I–III tumour. These data were presented 
only for women with colon cancer, as metachronous ovarian metastases were very uncommon 
in those with rectal cancer. Patients were allocated to one of three groups (no recurrence, ovar-
ian metastases and any other recurrence), and data for these groups were analysed separately.
Patients and Methods
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Paper IV
Women with rectal cancer were included at four high-volume centres for rectal cancer sur-
gery. The study design of the prospective, ongoing study is described in Fig. 8. The prima-
ry endpoint is sexual function after treatment, measured using the FSFI- questionnaire, de-
scribed on page 33 204. Secondary endpoints are psychological well-being, hormone levels 
after treatment and possible correlations between sexual function and androgen levels. When 
the study was planned, no normative FSFI data for women of the same age group were found 
in a PubMed search of the literature. Therefore, a previously performed power analysis based 
on FSFI data from younger women was used and in addition, a power analysis of a second-
ary endpoint, testosterone levels after radiotherapy, was performed. The estimated patient 
cohort size required to detect a significant treatment-related effect on the mean total FSFI 
score was 60–80 women. Inclusion criteria were women scheduled to undergo abdominal sur-
gery for stage I–III rectal cancer. Exclusion criterion was inability to give informed consent. 
When the initially planned sample size was reached, the question was raised as to whether this 
would actually be sufficient to demonstrate a measurable significant postoperative reduction of 
the mean total FSFI score, or if a larger sample size would be needed. Moreover, since a large 
proportion of eligible women were not included in the study, the possibility of a selection bias 
for those included had to be assessed.
In paper IV feasibility and internal and external validity were assessed. Women in the study 
cohort were compared with those who were eligible for inclusion, but not included, with re-
gard to clinical data and treatment. These data were obtained from the Swedish Rectal Cancer 
Registry. In the study cohort, sexual function was measured using FSFI, clinical data were 
collected, and blood samples were drawn. To avoid any negative influence of the recently di-
agnosed cancer on the pre treatment questionnaires, patients were asked to answer according 
to their situation before they experienced symptoms from the tumour. The FSFI scores were 
calculated irrespective of whether the women were sexually active or not. Domain scores were 
calculated for patients with complete responses in the corresponding items, and total scores 
were calculated for patients with complete responses in all items. 
In the final study, analysis of several biomarkers will be performed according to the study de-
sign (Fig. 8). In the present study, serum was analysed for total T, sex hormone-binding globu-
lin (SHBG), and plasma levels of albumin. In women under 55 years old, serum was analysed 
for reproductive hormones. Concentrations of free T were calculated from values for total T, 
SHBG, and albumin concentrations by successive approximation using a computer program 
based on an equation system derived from the law of mass action 227. Clinical data and T levels 
were compared for women who did and who did not complete all FSFI items. A new power 
analysis based on FSFI total scores of the first 82 patients included was performed.
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Figure 8. Design of the prospective study on sexual function and androgen levels in women with 
rectal cancer.
 
1. Androgens: Total testosterone (T), sex hormone-binding globulin (SHBG), androstenedione (A-
4), dehydroepiandrosterone-sulphate (DHEAS) 
2. Thyroid and parathyroid function: thyroxine (T-4), thyrotropin (TSH), parathyroid hormone 
(PTH), calcium, albumin 
3. Cortisol 
4. Anabolic function: Insulin-like growth factor 1 (IGF-1), Insulin-like growth factor binding protein 1 
(IGFBP-1), Insulin-like growth factor binding protein 3 (IGFBP-3) 
5. Bone markers: osteocalcin, carboxyterminal telopeptide of type 1 collagen (1CTP), 
carboxyterminal propeptide of type 1 procollagen (P1CP) 
6. Women < 55 years old: oestradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone 
(LH), progesterone, anti-mullerian hormone (AMH) 
 
 *Three possible radiotherapy regimens:  
5x5 Gray + operation within one week 
5x5 Gray + operation after four to eight weeks 
25x2 Gray + operation after four to eight weeks 
Serum or plasma analyses: 
Visit 1A – Before treatment 
PGWB 
FSFI 
Blood samples 
CRF 1A 
Women < 55 years old receive written 
information on additional blood samples before 
eventual hormone replacement therapy 
Preoperative radiotherapy* or 
radiochemotherapy 
 
Visit 1B – The day before surgery 
Blood samples 
CRF 1B 
 
Surgery 
Visit 2 – One year after surgery 
PGWB 
FSFI 
Blood samples 
CRF 2 
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Statistical analysis
Papers I–IV
Distributions were compared using the χ2 test of independence or Fisher’s exact test, as appro-
priate. Continuous variables such as age, time, and laboratory data were compared using the 
Mann-Whitney U test or the Kruskal-Wallis test. All tests were two-sided and p values below 
0.05 were considered statistically significant. 
In the analysis of event-specific rates, patients were considered to be at risk for the studied 
event until death or the end of follow-up. Survival and the cumulative incidence were esti-
mated using the Kaplan Meier method and the differences were assessed by the log-rank test. 
Cox proportional hazards regression was used to model the risk of not being assessed by the 
MDT with respect to potential confounding factors and to model the incidence of diagnosed 
metachronous PC with respect to different covariates. Results are presented as hazard ratios 
(HRs) or odds ratios (ORs) with corresponding 95% confidence intervals (CIs).
Ethics
All studies were approved by the Regional ethical review boards.
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resuLts And disCussion
Paper I
Differences in Multidisciplinary Team Assessment and Treatment between  
Patients with Stage IV Colon and Rectal Cancer
In all, 7894 patients were included in the Regional Quality Registry during the study period. 
In 1000 patients with colon cancer and 449 with rectal cancer, metastases were found at the 
time of diagnosis (study cohort). Of these, 689 (68.9%) colon cancer patients and 352 (78.4%) 
rectal cancer patients were assessed by an MDT and the proportion increased over the study 
period (P < 0.001). Surgery for metastases was done on 39 (3.9%) colon cancer patients and 
38 (8.5%) rectal cancer patients (P < 0.001). Colorectal cancer patients selected for metastasis 
surgery had 37% 5-year survival compared to 2% in patients not selected for metastasis surgery 
(P < 0.001).
Surgery
In the majority of the patients, the primary tumour was resected (722 of 1000 (72.2 %) in colon 
cancer patients vs 295 of 449 (65.7 %)(P = 0.012) in rectal cancer patients). In elective resec-
tions of the primary tumour, local tumour clearance was complete in 373 of 506 (73.7 %) colon 
cancer resections and 191 of 283 (67.5 %) rectal cancer resections (P = 0.063). For emergency 
resections, the corresponding figures were 133 of 216 (61.6 %) and 5 of 12 (41.7 %), respec-
tively (P = 0.240). 
There has been a shift to a more conservative management of the primary tumour in patients 
with disseminated disease where curative surgery is not possible. Palliative chemotherapy 
without surgery is often adviseable if there are no or only mild symptoms from the primary tu-
mour. Palliative radiotherapy is sometimes indicated for rectal cancers.  However, surgery with 
a diverting stoma, enteroanastomosis, stent or resection of the primary tumour may be necces-
sary in the case of bleeding, perforation, or obstruction. Careful evaluation and treatment plan-
ning in an MDT setting can help to avoid the morbidity of a surgical procedure with dubious 
benefit. According to 2009–2010 data from the Swedish Colon and Rectal Cancer Registries, 
66.8% vs 8.6% of stage IV colon and rectal cancers are resected 5 6. In an international study 
on rectal cancer management, departments with regular MDT meetings were more likely to 
treat synchronous liver metastases with new neoadjuvant chemotherapy and to avoid one-stage 
surgery of liver metastases and primary tumours 17. 
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Multidisciplinary Team Assessment
A smaller proportion of patients with colon cancer was assessed by the MDT: 68.9% vs 78.4% 
for those with rectal cancer. The proportion of MDT-assessed patients increased over the study 
period, from 58.6% to 76.3% for patients with colon cancer (P < 0.001) and from 72.4% to 
83.7% for patients with rectal cancer (P = 0.005), as shown by comparison of patients from 
1995 to 1999 vs those from 2000 to 2004. Improved oncological treatment and ongoing trials 
evaluating new chemotherapeutic drugs may have contributed to this increase in MDT assess-
ment over time. However, we used a wide definition of the term. During the early years of the 
study period, the MDT assessment was usually a structured discussion of treatment strategies 
involving just a surgeon and an oncologist. This has developed into today’s conferences where 
colorectal surgeons, a radiologist, an oncologist, a pathologist, specialized nurses, and occa-
sionally a liver surgeon are present. According to the Department of Health in the United King-
dom, an MDT is defined as a “group of people of different healthcare disciplines, which meets 
together at a given time (whether physically in one place, or by video or teleconferencing) to 
discuss a given patient and who are each able to contribute independently to the diagnostic and 
treatment decisions about the patient”  140.The wide definition in Paper I reflects the difficulty 
to determine an exact date when MDT conferences were set up in each individual hospital in 
the region, as this has developed gradually in different ways, and reported differently to the 
registries. For example, in one hospital, the postoperative discussion with the pathologist step 
by step became a pre-and postoperative discussion with both pathologist and oncologist, and 
later on, the radiologist was involved. Another hospital started up with magnetic resonance im-
aging (MRI) conferences discussing rectal cancer patients preoperatively with the radiologist, 
and the oncologist at the same department was contacted when needed. The colon and rectal 
cancer patients were treated in ten different hospitals in the region, including two university 
hospitals. Liver surgeons have been present at the MDT conferences in university hospitals but 
not in others. 
There may be several reasons why rectal cancer patients were more frequently assessed by the 
MDT than colon cancer patients in the current study. Above all, rectal cancer patients were 
younger and less frequently had surgery on an emergency basis. Another possible contributing 
factor is that, during the past three decades, there has been a focus in Sweden mainly on rectal 
cancer treatment with the addition of preoperative RT and the introduction of TME-based sur-
gery 3 47 159 160. 
In agreement with the present study, MDT assessment was more common in patients with 
rectal cancer than colon cancer in a population-based study from France 33. In that study, other 
factors associated with MDT assessment were age < 75 years, diagnosis established in univer-
sity hospitals, and advanced TNM stage. Overall, a multidisciplinary meeting was conducted 
for 32% of patients, with a wide variation between different geographical areas and types of 
hospitals. In the present study, factors associated with MDT assessment were age < 72 years, 
liver metastases only, and elective surgery. However, in this analysis, there is a risk of bias. 
For example, the most severely ill patients may be found in the ”No surgery” group. If they die 
before the MDT conference takes place, the risk of not being assessed by the MDT is exagger-
ated for this group, since only living patients are discussed. 
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Surgery for Metastases and Survival
During the follow-up time, 39 (3.9%) patients with colon cancer and 38 (8.5 %) patients with 
rectal cancer had surgery for metastases (P < 0.001). The most common procedure was hepatic 
resection. In total, metastasis surgery was more common among patients who were assessed by 
an MDT than among patients who were not (72 of 1041 (6.9%) vs 5 of 409 (1.2%) (P < 0.001)). 
Surgery for metastases was more common in patients with colorectal cancers diagnosed during 
the second half of the study period than the first (20 of 628 (3.2%) vs 57 of 821 (6.9%) (P < 
0.001)). Colorectal cancer patients selected for metastasis surgery had less extensive metastatic 
disease (data not shown) and were younger (63 (27 – 85) years vs 72 (23-97) years (P < 0.001)) 
than those who were not. As mentioned above, information on ASA classification or comorbid-
ity was not available in the register for the study period, but one can assume that there were 
differences between groups.
The overall survival rate after five years in all patients with stage IV colorectal cancer was 4% 
compared with 56% in patients with stage I–III tumours diagnosed during the same time period 
(P < 0.001). In patients with stage IV disease selected for metastatic surgery, the estimated 
survival after five years was 37% (Fig. 9). The 5-year survival rate is higher than that reported 
in other population-based studies, which ranged between 10.8% and 27.9% after resection of 
synchronous colorectal liver metastases and 21.6% after resection of synchronous and meta-
chronous colorectal metastases in all locations 55 97 146 156. One study has reported an association 
between assessment in an MDT including a liver surgeon and improved overall survival in 
colorectal cancer patients with liver metastases 149. Improved survival has also been reported 
for stage II–IV colorectal cancer patients after the inception of MDT conferences 150. Moreover, 
implementation of MDT conferences has been shown to select more rectal cancer patients to 
neoadjuvant treatment, to lower the rate of CRM involvement, and increase local tumour con-
trol 43 183. A positive association between MDT assessment and survival has also been reported 
for other malignancies in several studies 111. 
In the current study, patients who were not assessed by the MDT ran a significantly higher risk 
of dying than patients who were, after adjustment for available possible influencing factors in 
a multivariate model. Unfortunately, this analysis may suffer from confounding and immortal 
time bias. If the MDT discussion influences treatment decisions, an effect on survival is ex-
pected. However, if for example, ASA classification was included in the analysis, the positive 
prognostic effect of the MDT would probably decrease as there is probably a selection of less 
severely ill patients to be discussed by the MDT. Furthermore, the time between cohort entry (= 
diagnosis) and exposure (= MDT conference) is clearly ”immortal time”, causing a bias, since 
the exposed subjects must survive this period to be discussed by the MDT. Thus, classifying 
this ”immortal time” as exposed time provides the MDT group with an artificial survival ad-
vantage over the unexposed subjects.  
In summary, advances in radiological staging, improved surgical techniques, and an increasing 
complexity in radiotherapy and medical oncological treatment highlights the importance of the 
MDT assessment in both colon and rectal cancer patients in order to open up the opportunity 
for more aggressive treatment with better outcomes. Advanced age or emergency surgery is 
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no reason today to exclude patients with metastatic disease from an optimal treatment. MDT 
assessment is also important not least for patients whose only treatment option is palliative 
care: it saves unnecessary visits to oncologists and helps expedite contact with palliative care 
providers.
Figure 9. Overall survival of patients with colorectal cancer according to stage and 
metastasis surgery.
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Paper II
Incidence, Prevalence and Risk Factors for Peritoneal Carcinomatosis from Colorectal 
Cancer – a Population Based Study
In all, 11.124 patients with colorectal cancer were included in the Regional Quality Registry 
during the study period. Nine hundred and twenty-four (8.3%) of these had synchronous or 
metachronous PC. PC was the first and only localization of metastases in 535 patients (4.8%). 
The prevalence of synchronous PC at the time of diagnosis of the primary tumour was 4.3% 
(477 of 11.124). The cumulative incidence of metachronous PC was 4.2% (447 of 10.646). 
Independent predictors for metachronous PC were age > 70 years, colon cancer, advanced T 
stage, advanced N stage, emergency surgery, and non radical resection of the primary tumour.
Previously, small retrospective follow-up studies published before the era of modern chemo-
therapeutics have reported metachronous PC in 2–19% after curative surgery 131. More re-
cently, Jayne et al. reported synchronous and metachronous PC in 7% and 4.5% respectively, 
in a retrospectively analysed series of 3019 patients with colorectal cancer treated at a tertiary 
referral centre for much of south-east Asia, which presents geographical problems for long 
term follow-up 117. 
The present study on all patients with colorectal cancer in a large, geographically defined, 
population showed a prevalence of 4.3% for synchronous PC and a cumulative incidence dur-
ing follow-up of 4.2% for metachronous PC. The thorough review of the registers and medical 
records probably identified most of the diagnosed cases of PC. Nevertheless, asymptomatic 
PC may have been missed since the intensity of follow-up has varied during the study period. 
PC may also not have been diagnosed in patients already diagnosed with disseminated disease, 
where the only treatment option is palliative. In addition, the autopsy rate was low during the 
study period 223.
Risk factors
Metachronous PC was found in 447 of 10.646 (4.2%) colorectal cancer patients. Uni- and 
multivariate analyses of risk factors for developing metachronous PC were performed for 7799 
patients who underwent abdominal resection of a primary colorectal cancer stage I–III and who 
were alive 30 days postoperatively. Metachronous PC was diagnosed during follow-up in 380 
of these patients (4.9%) after a median period of 16 (range 1.4 to 142) months after surgery. 
Independent predictors for developing metachronous PC were colon cancer, particularly right-
sided, tumour stage T3 to T4, lymph node stage N1 to N2, less than 12 lymph nodes examined, 
emergency procedures, and non-radical resections of the primary tumour (R1 to R2). Patients > 
70 years of age had a decreased risk of metachronous PC (Table 5). In the study by Jayne et al., 
liver metastases, tumour stage, nodal stage, and venous and perineural tumour invasion were 
independent predictors for the development of metachronous PC following curative resection 
117. Other suggested risk factors are limited PC at the primary operation, ovarian metastases and 
perforated or obstructive primary tumours 71 264. 
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Knowledge concerning predictors and time to recurrence is essential if early diagnosis of PC 
and aggressive treatment with curative intent is considered.  Some authors advocate second-
look surgery in patients at high risk of developing PC 71 145 169 236. Two ongoing prospective 
randomized controlled trials evaluate second-look surgery with HIPEC and CRS versus stan-
dard-of-care surveillance in patients at high risk of developing colorectal PC 50 202. In these 
studies, second-look surgery is performed either after six months of adjuvant chemotherapy or 
12 months after the primary operation. 
Prophylactic treatment using the HIPEC procedure to prevent development of PC is also being 
discussed for T4 carcinomas 256. In the current study, the risk of metachronous PC was 10-fold 
higher after resection of a T4 tumour compared to T1. Among those with resected T4 tumours, 
259 (27.8%) of 934 patients with colon cancer and 22 (10.8%) of 204 with rectal cancer were 
diagnosed with synchronous or metachronous PC (P<0.001). Subclassification of T4 stage 
was only available for tumours diagnosed during the last year of the study. In these patients, 
PC was more common in cases of tumour penetration to the surface of visceral peritoneum 
than in tumour invasion of other organs (20 of 71 vs 3 of 27) (P = 0.075) although this did not 
reach statistical difference. An association between local peritoneal involvement and PC for 
rectal cancer has previously been reported 167. The increased risk for patients with T4 tumours 
could be taken into account when deciding upon follow-up regimens. In patients with several 
risk factors, in particular high T-stage, who are expected to tolerate CRS and HIPEC, a close 
follow-up with computed tomography and determination of CEA level would be appropriate. 
The value of second-look surgery with the possibility of CRS and HIPEC, or HIPEC concomi-
tantly with resection of the primary tumour, remains to be determined. 
Ovarian Metastases and Peritoneal Carcinomatosis
Ovarian metastases were more common in women diagnosed with PC and vice versa. Syn-
chronous and metachronous metastases taken together, among all 98 women with ovarian me-
tastases, PC was diagnosed in 64 women (65%). This is consistent with a cohort study on 103 
women with synchronous or metachronous ovarian metastases from colorectal cancer, 52% of 
whom were diagnosed with synchronous PC 127. In the current study, among the 483 women 
with PC, ovarian metastases were diagnosed in 64 (13%). This figure is less compared to a 
previous study reporting micro- or macroscopic ovarian metastases in 52% of 194 women un-
dergoing CRS and HIPEC for peritoneal carcinomatosis of colorectal origin 74.
Survival
In total, 36 colon cancer patients and one rectal cancer patient from the cohort were operated 
on for PC at the referral center during the study period. The procedures performed were CRS 
in 26 patients, debulking surgery in eight patients and only laparotomy without resection in 
three patients. Surgery was combined with intraabdominal chemotherapy in all cases where 
resection was performed. The estimated median survival from diagnosis of PC in the 34 pa-
tients undergoing CRS or debulking surgery was 26.9 (95% CI, 18.3 to 31.5) months, which is 
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similar to that previously reported 70 79 154 238 257 258 . The corresponding figure for the heteroge-
neous group of all patients with PC was 5.6 months (95% CI, 4.8 to 6.4), excluding 17 cases 
of PC diagnosed at autopsy. Five-year survival rates for these groups are presented in Fig. 10. 
However, to report the outcome related to treatment of PC was not a primary aim of this study. 
Nevertheless, there is increasing evidence today showing that in selected patients with PC, 
CRS and HIPEC improve survival. 
In summary, colorectal PC was common in the present population-based study. Patients with 
colon cancer, particularly right-sided, advanced tumour and node status, and emergency and 
Predictor No. of 
patients 
(n=7799)
No with 
pc
Multivariable  
analysis  
Hazard ratio
p
Age < 49 367 28 1.2 (0.8–1.8) 0.003
49–70 2662 162 1.0
> 70 4770 190 0.7 (0.6–0.9)
Tumour site Right colon 2366 149 1.8 (1.3–2.4) 0.002
Transverse 
colon
523 26 1.2 (0.8–1.9)
Left colon 2273 129 1.5 (1.1–2.0)
Colon NOS 1 0
Rectum 2636 76 1.0
Tumour status T0 or T1 10+412 0+5 1.0 < 0.001
T2 1423 8 0.6 (0.2–2.3)
T3 5285 261 3.8 (1.2–12.0)
T4 628 106 10.0 (3.1–32.1)
Data missing 41 0
Node status* N0 (> 12) 1696 36 1.00 < 0.001
N0 (< 12) 2986 87 1.7 (1.2–2.6)
N1 (> 12) 629 32 2.2 (1.3–3.5)
N1 (< 12) 1115 86 3.8 (2.5–5.6)
N2 (> 12) 643 76 4.7 (3.1–7.1)
N2 (< 12) 424 54 7.4 (4.8–11.5)
Data missing 306 9
Type of surgery Elective 6843 270 1.0 < 0.001
Emergency 956 110 2.1 (1.7–2.7)
Radicality R0 6864 254 1.0 < 0.001
R1 224 31 2.0 (1.3–2.9)
R2 594 85 2.8 (2.1–3.6)
Data missing 117 10 1.2 (0.6–2.6)
Adjuvant  
chemotherapy**
No 6644 263 1.0 0.024
Yes 1153 117 0.7 (0.6–1.0)
Data missing 2 0
Values in parentheses are 95% confidence intervals unless indicated otherwise; * values are numbers 
of nodes examined; ** Within 3 months of the primary operation.
Table 5. Cox proportional regression analysis of predictors for developing metachronous perito-
neal carcinomatosis in patients alive 30 days after abdominal resection of stage I–III colorectal 
cancer.
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non-radical procedures had an increased risk of developing metachronous PC. Defining risk 
factors may be important for early diagnosis and may help to select patients for aggressive 
treatment with curative intent.
Figure 10a. Five-year survival from the diagnosis of peritoneal carcinomatosis for all patients with 
peritoneal carcinomatosis.
Figure 10b. Five-year survival from diagnosis of peritoneal carcinomatosis in 34 patients treated 
with cytoreductive surgery and intraperitoneal chemotherapy.
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Paper III
Epidemiology and Prognosis of Ovarian Metastases from Colorectal Cancer
In all, 4566 women with colorectal cancer, without a previous history of gynaecological cancer, 
were included in the study cohort. Overall, synchronous and metachronous ovarian metastases 
were more common in women with colon cancer than in those with rectal cancer and were 
found in 69 of 3172 (2.2%) and 10 of 1394 (0.7%) respectively (P < 0.001).  The prevalence 
of synchronous ovarian metastases at the time of diagnosis of the primary tumour was 0.9% 
(42 of 4566 ) for all colorectal cancer patients, 1.1 % (34 of 3172) among women with colon 
cancer, and 0.6% (8 of 1394) among those with rectal cancer (P = 0.105).  
Metachronous ovarian metastases were found in 37 of 4527 (0.8%) of all colorectal cancer 
patients, or 35 of 3144 (1.1%) patients with colon cancer and two of 1383 (0.1%) with rectal 
cancer (P<0.001). Patients with colon cancer who developed ovarian metastases were younger, 
had a more advanced tumour stage and more often underwent emergency surgery for the pri-
mary tumour than those without a recurrent malignancy during follow-up. Survival in patients 
with ovarian metastases was poor.
Earlier single-centre studies report synchronous ovarian metastases in 0–9% of women with 
colorectal cancer and metachronous ovarian metastases in 0.9 –7% 93 101 127 209 274. In the current 
study, asymptomtomatic ovarian metastases may be underdiagnosed for the same reasons as 
described for PC in paper II. Ovarian metastases were more common in patients with colon 
cancer than those with rectal cancer. One reason for this could be that carcinomatosis, with an 
increased risk of peritoneal spread to the ovaries, is more common in colon cancer patients than 
in rectal cancer patients 215.  Another contributing factor could be that nearly half of the women 
with rectal cancer were treated with radiotherapy. The effect of preoperative radiotherapy on 
the ovaries is unclear in women with rectal cancer. One possibility could be that radiotherapy 
itself eradicates micrometastases in the ovaries but also causes ovarian atrophy and impairs the 
ovarian blood supply, and thereby reduces the risk of haematogenous spread of the colorectal 
cancer to the ovaries.
In total, unilateral oophorectomy was performed in 22 of 4566 (0.5%) and bilateral oophorec-
tomy in 60 of 4566 (1%) women with colorectal cancer during the study period. Sixty-nine 
of these had ovarian metastases, three had direct overgrowth of the primary colorectal cancer, 
and ten had no pathology in the ovaries, but either distant metastases at other sites (n = 9) or a 
suspicion of ovarian involvement (n = 1). 
Among patients with potentially cured colorectal cancer, e.g. patients with R0-resected colorec-
tal cancer presenting with stage I–III disease, metachronous ovarian metastases were found in 
22 of 1971 patients (1.1%) with colon cancer and one of 881 (0.1%) with rectal cancer (P = 
0.006). The ovarian metastases were diagnosed after a median period of 16 (2–50) months 
from resection of the primary tumour. In colon cancer patients who developed metachronous 
ovarian metastases compared with those who did not, tumour stage was more advanced and 
emergency surgery was more common (P < 0.001). They were also younger (P < 0.001), which 
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may be a result of a decreasing risk of haematogenous tumour spread to atrophic ovaries in old-
er women. This is in accord with other studies reporting an even lower median age in women 
developing ovarian metastases from colorectal cancer 49 127 147 198 240 . 
Survival in patients with ovarian metastases was poor. The estimated 5-year overall survival 
from diagnosis in all patients with synchronous ovarian metastases was 11 (CI 0.4–21) %. 
Other recent studies have reported a 25% 3-year survival and 27–44% 5-year survival in pa-
tients with synchronous ovarian metastases 49 80 127.  After complete resection of the malignant 
disease, reported 5-year disease-free and overall survival were 40% and 61%, respectively 80 
127. In the current study, survival of women with colon cancer who developed metachronous 
ovarian metastases was as poor as that of patients with other recurrences (Fig. 11).
In the discussion regarding prophylactic oophorectomy, it is of value to know the risk of de-
veloping metachronous ovarian metastases. In summary, this study shows that metachronous 
ovarian metastases from colorectal cancer are uncommon, and this does not favour routine pro-
phylactic oophorectomy. More important factors to consider prior to surgery are the patient’s 
age, individual risk of primary ovarian, breast and endometrial cancer, desire to preserve her 
hormone status and, not least, her own wishes. 
Figure 11. Overall survival after R0 resection of stage I–III colon cancer, grouped according 
to recurrence. P < 0.001 (log rank test)
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Paper IV
Potential Selection Bias in a Prospective Study on Sexual Function and Androgen 
Levels in Women with Rectal Cancer 
The 82 women in the study cohort were younger than the 75 women who were eligible for in-
clusion but were not included (age 63 vs age 67, P = 0.002). There was a difference in the ASA 
classification, with lower comorbidity in the group of women who were included vs those who 
were not (P = 0.025). Clinical data and blood samples were obtained from all women in the 
study cohort. Serum levels of total testosterone (T) were above the detection limit in 76 women 
(92.7%). Fifty-seven women (69.5%) completed all the FSFI items. The proportion of women 
who had a partner was higher in this group compared with the women who did not complete all 
the FSFI items (49 out of 57 (86.0%) vs 7 out of 25 (28.0%) (P < 0.001).
Selection Bias
In total, treatment for rectal cancer was initiated in 237 women at the four study centres dur-
ing the study period (Fig. 12). One hundred and fifty-seven of these women (66.2%) were 
eligible for inclusion in the study. In all, 82 of the 157 (52.2%) eligible women were included 
at the time of analysis. The reasons for not entering the study are shown in Fig. 12. Forty-two 
women were never invited to participate, thirty-two declined to join the study, and one was not 
included for unknown reasons. 
Patients treated at the study centres might not be representative of the total population of female 
rectal cancer patients, which may reduce the external validity. Non-Swedish-speaking women 
were not included, and there may be demographic differences in, for example, educational 
level and socioeconomic or marital status between the study cohort and the total population 
of female rectal cancer patients. In addition, all four centres are high-volume ones with a high 
proportion of patients undergoing complete preoperative staging with pre- and post operative 
MDT assessments, which may influence treatment and outcome 6 215. One of the centres is a 
referral centre for advanced tumours, which may explain the relatively high proportion of cT4 
tumours (28% of patients eligible for inclusion). This can be compared with the 17% propor-
tion of cT4 tumours in all Swedish patients undergoing abdominal resection of a rectal cancer 
stage I–IV 2010 6.
An analysis of patient characteristics in all eligible women revealed a selection bias. Women 
in the study cohort were younger than the women who were not included (age 63 vs age 67, P 
= 0.002). There was also a difference in the distribution of ASA classification, with a lower co-
morbidity in the group of women who were included vs those who were not (P = 0.025). The 
bias consists of both self-selection by declining to join and investigator-selection by not invit-
ing to join. Over time, investigator-selection has decreased as a growing proportion of finally 
eligible women were invited to enter the study. A low inclusion rate has previously been re-
ported in studies evaluating sexual function in women with rectal cancer 39 116 192. Low response 
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rates to questionnaires or avoidance of specific items regarding sexual function is another im-
portant limitation, particularly in female patients 108 116 218 265. Response rates of less than 50% 
are common. 30 96 108 218 242.In the present study, 57 women (69.5%) completed all nineteen FSFI 
items (complete FSFI responders) and 25 (30.5%) did not (incomplete FSFI responders). The 
proportion of women who had a partner was significantly higher in the group of complete FSFI 
responders than in those who were incomplete FSFI responders (49 of 57 (86.0%) vs 7 of 25 
(28.0%) (P < 0.001)). The largest amount of missing or invalid data was found in two of the 
satisfaction items that cannot be adequately answered by sexually inactive individuals. These 
items concern satisfaction with the sexual relationship with the partner and overall sexual life, 
and there is no answer option such as “not relevant”.
Figure 11. Flow-chart for inclusion in the study 
 
 
    
All women with rectal cancer treated 
at the four study centres  
n = 237 
 
Did not meet the inclusion criteria, n = 71 
    Stage IV (verified or suspicion of), n = 43 
    Radiotherapy started before admission to study centre, n=21 
    Emergency surgery,  n = 1 
    Local excision of primary tumour, n = 6 
Eligible for inclusion 
n = 157 
Not included, n = 75 
    Declined to join the study, n = 32 
    Not invited to join the study, n = 42 
     Unknown, n = 1 
Included 
n = 82 
Incomplete responders to FSFI 
n = 25 
Complete responders to FSFI 
n = 57 
Women with stage I-III rectal cancer, 
scheduled to undergo abdominal 
surgery, n = 166 
 
Exclusions n = 9 
    Not able to give informed consent, n = 5 
    Non-Swedish-speaking, n = 2 
    Short life-time expectancy, n = 2 
Figure 12. Flow-chart for inclusion in the study
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As a consequence, mean and median total FSFI scores are representative for a subgroup of the 
cohort and may exclude women who have the poorest sexual function. The domain scores rep-
resent women who responded to the corresponding items in that specific domain and therefore 
better reflect the sexual function of the entire study cohort. Differences between included vs not 
included women reduce the external validity and differences between complete vs incomplete 
FSFI responders reduce the internal validity. 
Feasibility
Feasibility was good. When the initial inclusion rate was slow, reminders at every MDT confer-
ence and regular updates of the number of patients included per centre were issued by e-mail. 
As a result, the proportion of women eligible for inclusion invited to join the study increased 
to nearly 100% during the study period at least in two of the centres (data not shown). Blood 
samples were drawn and clinical data obtained from all women in the study cohort. Compli-
ance was high concerning FSFI data, with a total response frequency to all 19 FSFI items of 
1459 of 1558 (93.6%). Incomplete FSFI responses appeared to be mainly an effect of question-
naire design. Seventy-six women (92.7%) had total T at or above the lowest level for detection, 
thus indicating active ovarian androgen production and adequate hormone measurements. 
Information Bias
The FSFI assesses six aspects of female sexual function (desire, arousal, lubrication, orgasm, 
sexual satisfaction, and dyspareunia) 204. Sexual activity is clearly defined as caressing, foreplay, 
masturbation, or vaginal intercourse, thus not excluding women without a partner. However, 
the FSFI is validated only for sexually active women, although it is used in studies including 
both women who are and who are not sexually active, which complicates the interpretation of 
data 58 108 116 148 165. The FSFI provides a total score, ranging from 2 to 36. A high FSFI total score 
represents good sexual function, while a low score could signify dysfunction and/or sparse 
sexual activity.  The absence of sexual activity resulting in low scores could be interpreted as 
a surrogate marker for sexual dysfunction. On the other hand, sexual inactivity may be a result 
of an individual’s lack of desire or opportunity for sexual activity and may not be an accurate 
reflection of physiological functionality.  This methodological limitation of FSFI has been dis-
cussed and suggestions for improvement have been published, but not yet implemented 29 84 166. 
It is important to note that the FSFI total score cut-off for sexual dysfunction (26.5) has been 
established for sexually active women, using data from a group with a mean age of 36 years 262. 
In the current study, 29 of the 41 sexually active complete responders (70.7%) had a total FSFI 
score of < 26.5, which indicates sexual dysfunction. Mean and median total FSFI scores for all 
the complete FSFI responders were 16.4 + 10.6 (SD) and 15.1 (range 2–32.3), respectively.  
To the best of our knowledge, there is no validated instrument for measuring sexual function 
in sexually inactive women. The frequently used EORTC QLQ–CR38 systematically ex-
cludes sexually inactive women 230. In the updated CR29, one of two items on sexual function 
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concerns dyspareunia and cannot be answered by women not including vaginal intercourse 
in their sexual activities 261. 
An additional possible source of information bias is recall bias. In our study the women are in-
structed to answer the questionnaires according to the situation before they experienced symp-
toms from the tumour. Patient delay is sometimes considerable for rectal cancer symptoms, 
which may influence baseline data. However, to minimize recall bias, the study design was 
prospective.
Power
We hypothesized that the mean total FSFI score at baseline would decrease by at least 20% 
after treatment. A sample size of 99 women will have an 80% power to detect a difference in 
means of 3.020 (20% impairment), assuming a standard deviation of differences of 10.58, us-
ing a paired t-test with a 0.05 two-sided significance level. When loss-to-follow-up is account-
ed for, the new estimated sample size is 130 women. The initially planned cohort size of 60–80 
women would not be sufficient to confirm the hypothesis concerning the primary outcome. The 
decision has been taken to continue inclusion of patients, now aiming for 130 women.
In summary, feasibility and patient compliance was good. Internal and external validity may be 
hampered by bias, in particular selection bias. The effect of selection bias on external validity 
may decline with a growing proportion of eligible women invited to enter the study. Accord-
ing to a new power analysis, a larger sample size than initially planned for is needed. Inclusion 
continues. 
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ConCLusions
-    Patients with stage IV colon cancer were less often assessed by a multidisciplinary team 
(MDT) and less often had metastasis surgery than stage IV rectal cancer patients. The 
proportion of patients with stage IV colon and rectal cancer assessed by an MDT increased 
during the study period, as did the proportion who had surgery for the metastases. MDT 
assessment opens up the opportunity for more aggressive treatment with better outcomes.
-       Peritoneal carcinomatosis (PC) from colorectal cancer was common. Independent predictors 
for metachronous PC were age > 70 years, colon cancer, advanced T stage, advanced N 
stage, emergency surgery and non-radical resection of the primary tumour. Defining risk 
factors for peritoneal carcinomatosis may be important for early diagnosis and may help to 
select patients for aggressive treatment with curative intent.
-     Ovarian metastases from colorectal cancer were uncommon. This does not support routine 
prophylactic oophorectomy in women with colorectal cancer. Patients developing ovarian 
metastases were younger, had a more advanced tumour stage, and more often underwent 
emergency surgery than those without a recurrence. Survival in colorectal cancer patients 
with ovarian metastases was poor.
-   Feasibility was good and patient compliance was high in the ongoing study on sexual 
function and androgen levels in women with rectal cancer. Internal and external validity 
may be limited by bias, in particular selection bias. The effect of selection bias on external 
validity may decrease with a growing proportion of eligible women invited to enter the 
study.
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PoPuLärvetenskAPLig 
sAmmAnfAttning På svenskA
Kolorektalcancer – aspekter på multidisciplinärt omhändertagande, 
metastaserande sjukdom och sexuell funktion
Bakgrund
Årligen drabbas drygt 6000 svenskar av kolorektalcancer (cancer i tjocktarm och ändtarm). 
Hos ungefär var femte patient har cancern redan hunnit sprida sig till andra organ när den 
upptäcks. Hur många patienter som drabbas av metastaser (dottertumörer) i specifika organ, t 
ex äggstockar eller bukhinna, är mindre känt. Även kunskapen om riskfaktorer för metastaser 
i olika organ är begränsad. 
Kirurgisk och onkologisk behandling av kolorektalcancer och metastaser har utvecklats och 
förbättrats avsevärt de senaste decennierna. Den primära behandlingen är operation, som ofta 
kombineras med onkologisk behandling. T ex ges ofta tilläggsbehandling med cellgift efter 
operation för koloncancer (tjocktarmscancer) eller strålbehandling mot primärtumören inför 
operation av rektalcancer (ändtarmscancer). Hos patienter med metastaser i andra organ kan 
cellgiftsbehandling förlänga överlevnaden och förbättra livskvaliteten. Hos ett mindre andel av 
patienterna med metastaserande sjukdom är det möjligt att utföra ett botande kirurgiskt ingrepp 
som innefattar både primärtumör och metastaser. Även i detta fall kombineras kirurgin ofta 
med onkologisk behandling. 
Metastaskirurgi görs framför allt vid begränsad levermetastasering, som är den vanligaste 
metastaslokalisationen. Även vid metastaser t ex till lunga, bukhinna eller äggstockar kan bo-
tande kirurgi vara möjlig. 
De ökade behandlingsmöjligheterna har medfört ett behov av att diskutera behandlingsalterna-
tiv för patienter med kolorektalcancer i s k multidisciplinära team, MDT. Det multidisciplinära 
teamet består av kirurger, onkologer, röntgenläkare, patologer och specialistsjuksköterskor. 
Huvudsyftet är att besluta om optimal behandling för varje enskild patient, men också att un-
derlätta kommunikation mellan olika vårdgivare och koordination av behandlingen.
Målet med behandlingen är bot eller maximal överlevnad. I takt med att behandlingsresultaten 
förbättrats har andra värden som livskvalitet och bieffekter av cancer och cancerbehandling 
blivit allt viktigare. Sexuell funktion har betydelse för livskvaliteten. Många studier har visat 
att den sexuella funktionen försämras efter strålbehandling och operation av rektalcancer hos 
manliga patienter. Detta har även påvisats hos kvinnliga patienter, men det vetenskapliga un-
derlaget är svagare.  
Bidragande orsaker till sexuell dysfunktion hos kvinnor och män som behandlats för rektal-
cancer kan vara effekter av det kirurgiska traumat, men också en minskad produktion av an-
drogener (könshormoner). Hos kvinnor i alla åldrar produceras androgener i binjurebarken och 
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i äggstockarna. En möjlig biverkan av strålbehandling vid rektalcancer skulle kunna vara en 
minskad androgenproduktion i äggstockarna, men hittills har inga studier om detta publicerats. 
Androgenbrist hos kvinnor är bl a associerat med nedsatt sexuell funktion och psykologiskt 
välbefinnande.
Metoder och resultat
Delarbete I-III är stora s k populationsbaserade kohortstudier, som baseras på alla patienter 
med kolorektalcancer i Stockholmsregionen under en definierad tidperiod. Styrkan med po-
pulationsbaserade studier är att kohorten representeras av alla patienter i en geografiskt väl-
definierad källpopulation (alla invånare i Stockholms Läns Landsting). Därmed undviks se-
lektionsbias. Selektionsbias innebär att gruppen av studerade patienter skulle utgöras av en 
specifik, utvald grupp patienter som särskiljer sig från hela gruppen av kolorektalcancerpatien-
ter. När selektionsbias minimeras ökar studiens generaliserbarhet, vilket innebär att resultaten 
från studien kan anses gälla för kolorektalcancerpatienter i allmänhet. 
I delarbete I studeras i vilken utsträckning patienter med fjärrmetastaser bedöms av det multi-
disciplinära teamet, samt effekten av detta. Såväl MDT-bedömning som kirurgi av metastaser 
var vanligare vid rektalcancer än vid koloncancer, och andelen patienter som bedömdes multi-
disciplinärt ökade över tid. Den utvalda minoriteten patienter som bedömdes lämpliga för och 
genomgick metastaskirurgi hade en avsevärt längre överlevnad jämfört de patienter som inte 
genomgick metastaskirurgi.
Delarbete II visar att metastasering till bukhinnan, peritoneal karcinos, är vanligt. Riskfaktorer 
för peritoneal carcinos var koloncancer, avancerat stadium avseende primärtumör och lymf-
körtlar, få undersökta lymfkörtlar, akutkirurgi och en icke-radikal resektion av primärtumören. 
Patienter över 70 år hade en minskad risk för peritoneal karcinos.
Delarbete III visar att metastaser till äggstockar, ovarialmetastaser, är ovanligt, ff a vid rektal-
cancer. Patienter som drabbades av ovarialmetastaser var yngre, hade ett mer avancerat tumör-
stadium och genomgick oftare akutkirurgi jämfört de som inte hade ovarialmetastaser. Över-
levnaden hos patienter med ovarialmetastaser var kort.
Delarbete IV utvärderar genomförbarhet, generaliserbarhet och selektionsbias i en pågående 
studie om sexuell funktion och hormonnivåer hos kvinnor som behandlas för rektalcancer. 
Något förenklat mäts sexuell funktion (med frågeformulär) och hormonnivåer (med analys av 
blodprov) hos kvinnorna i studien före behandling och ett år efter behandling. Inför studiestart 
beräknades att en studiekohort på 60-80 kvinnor skulle vara tillräcklig för att påvisa den hypo-
tetiska försämringen i sexuell funktion efter behandlingen. 
I delarbete IV analyseras data från alla potentiellt inkluderbara patienter. Jämförelse av data 
från de 82 dittills inkluderade kvinnorna (studiekohorten) med de som inte inkluderades visar 
selektionbias. Patienterna i studiekohorten var något yngre och hade tidigare tumörstadium 
jämfört de som inte inkluderades. Dock har studiekohorten som grupp ett avancerat tumörsta-
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dium vid en nationell jämförelse. Det kan förklaras av att ett av de fyra sjukhusen som är med i 
studien är ett centrum för avancerad rektalcancerkirurgi, vilket avspeglas i patientklientelet.
Följsamheten hos patienterna i studiekohorten var hög. Alla lämnade blodprov, och majoriteten 
av frågorna i frågeformuläret besvarades. Att ha en partner och vara sexuellt aktiv var vanligare 
hos de patienter som besvarade alla frågorna jämfört de som inte gjorde det. Frågorna som 
oftast lämnades obesvarade är ställda på ett sådant sätt att de saknar relevans för den som inte 
har ett aktivt sexliv med en partner. 
Baserat på enkätdata före behandling gjordes en ny analys avseende hur stort antal patienter 
som krävs för att bekräfta hypotesen. Analysen visade att patientgruppen skulle behöva vara 
större än tidigare beräknat.
Konklusion
Sammanfattningsvis visar avhandlingen att en ökande andel patienter med metastaserande ko-
lorektalcancer bedömdes på MDT-konferens och genomgick metastaskirurgi. 
Förekomsten av och riskfaktorer för peritoneal carcinos och ovarialmetastaser definierades, 
vilket kan underlätta beslut om behandling och uppföljning. 
Analys av data från studien om sexuell funktion och hormonnivåer hos kvinnor med rektal-
cancer visar god genomförbarhet men viss selektionsbias. Inklusionen av patienter i studien 
fortsätter.
Summary in Swedish
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Female Sexual Function Index (FSFI) 
Subject Identifier ________________________          Date ________________
INSTRUCTIONS: These questions ask about your sexual feelings and responses
during the past 4 weeks.  Please answer the following questions as honestly and
clearly as possible.  Your responses will be kept completely confidential. In
answering these questions the following definitions apply:
Sexual activity can include caressing, foreplay, masturbation and vaginal intercourse.
Sexual intercourse is defined as penile penetration (entry) of the vagina.
Sexual stimulation includes situations like foreplay with a partner, self-stimulation
(masturbation), or sexual fantasy.
CHECK ONLY ONE BOX PER QUESTION.
Sexual desire or interest is a feeling that includes wanting to have a sexual
experience, feeling receptive to a partner's sexual initiation, and thinking or
fantasizing about having sex.
1. Over the past 4 weeks, how often did you feel sexual desire or interest?
Almost always or always
 Most times (more than half the time)
Sometimes (about half the time)
A few times (less than half the time)
Almost never or never
2. Over the past 4 weeks, how would you rate your level (degree) of sexual desire
or interest?
Very high
High
Moderate
Low
Very low or none at all
APPendix
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Sexual arousal is a feeling that includes both physical and mental aspects of sexual
excitement. It may include feelings of warmth or tingling in the genitals, lubrication
(wetness), or muscle contractions.
3. Over the past 4 weeks, how often did you feel sexually aroused ("turned on")
during sexual activity or intercourse?
No sexual activity
Almost always or always
Most times (more than half the time)
Sometimes (about half the time)
A few times (less than half the time)
Almost never or never
4. Over the past 4 weeks, how would you rate your level of sexual arousal ("turn
on") during sexual activity or intercourse?
No sexual activity
Very high
High
Moderate
Low
Very low or none at all
5. Over the past 4 weeks, how confident were you about becoming sexually
aroused during sexual activity or intercourse?
No sexual activity
Very high confidence
High confidence
Moderate confidence
Low confidence
Very low or no confidence
6. Over the past 4 weeks, how often have you been satisfied with your arousal
(excitement) during sexual activity or intercourse?
No sexual activity
Almost always or always
Most times (more than half the time)
Sometimes (about half the time)
A few times (less than half the time)
Almost never or never
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7. Over the past 4 weeks, how often did you become lubricated ("wet") during
sexual activity or intercourse?
No sexual activity
Almost always or always
Most times (more than half the time)
Sometimes (about half the time)
A few times (less than half the time)
Almost never or never
8. Over the past 4 weeks, how difficult was it to become lubricated ("wet") during
sexual activity or intercourse?
No sexual activity
Extremely difficult or impossible
Very difficult
Difficult
Slightly difficult
Not difficult
9. Over the past 4 weeks, how often did you maintain your lubrication ("wetness")
until completion of sexual activity or intercourse?
No sexual activity
Almost always or always
Most times (more than half the time)
Sometimes (about half the time)
A few times (less than half the time)
Almost never or never
10. Over the past 4 weeks, how difficult was it to maintain your lubrication
("wetness") until completion of sexual activity or intercourse?
No sexual activity
Extremely difficult or impossible
Very difficult
Difficult
Slightly difficult
Not difficult
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11. Over the past 4 weeks, when you had sexual stimulation or intercourse, how
often did you reach orgasm (climax)?
No sexual activity
Almost always or always
Most times (more than half the time)
Sometimes (about half the time)
A few times (less than half the time)
Almost never or never
12. Over the past 4 weeks, when you had sexual stimulation or intercourse, how
difficult was it for you to reach orgasm (climax)?
No sexual activity
Extremely difficult or impossible
Very difficult
Difficult
Slightly difficult
Not difficult
13. Over the past 4 weeks, how satisfied were you with your ability to reach orgasm
(climax) during sexual activity or intercourse?
No sexual activity
Very satisfied
Moderately satisfied
About equally satisfied and dissatisfied
Moderately dissatisfied
Very dissatisfied
14. Over the past 4 weeks, how satisfied have you been with the amount of
emotional closeness during sexual activity between you and your partner?
No sexual activity
Very satisfied
Moderately satisfied
About equally satisfied and dissatisfied
Moderately dissatisfied
Very dissatisfied
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15. Over the past 4 weeks, how satisfied have you been with your sexual
relationship with your partner?
Very satisfied
Moderately satisfied
About equally satisfied and dissatisfied
Moderately dissatisfied
Very dissatisfied
16. Over the past 4 weeks, how satisfied have you been with your overall sexual life?
Very satisfied
Moderately satisfied
About equally satisfied and dissatisfied
Moderately dissatisfied
Very dissatisfied
17. Over the past 4 weeks, how often did you experience discomfort or pain during
vaginal penetration?
Did not attempt intercourse
Almost always or always
Most times (more than half the time)
Sometimes (about half the time)
A few times (less than half the time)
Almost never or never
18. Over the past 4 weeks, how often did you experience discomfort or pain following
vaginal penetration?
Did not attempt intercourse
Almost always or always
Most times (more than half the time)
Sometimes (about half the time)
A few times (less than half the time)
Almost never or never
19.Over the past 4 weeks, how would you rate your level (degree) of discomfort or
pain during or following vaginal penetration?
Did not attempt intercourse
Very high
High
Moderate
Low
Very low or none at all
Thank you for completing this questionnaire
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